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	 2	
	
Signaling of the epithelial splicing variant of the fibroblast growth factor 
receptor 2 (FGFR2b) induces both autophagy and phagocytosis in human 
keratinocytes. In this work I investigated, in our cell model of HaCaT 
keratinocytes, if the two processes might be related and the possible involvement 
of PLCγ signaling in the autophagy triggered by FGFR2b activation. Using 
fluorescence and electron microscopy we demonstrated that the FGFR2b-induced 
phagocytosis and autophagy involve converging autophagosomal and 
phagosomal compartments. Moreover, the forced expression of FGFR2b signaling 
mutants and the use of specific inhibitors of FGFR2b substrates showed that the 
receptor-triggered autophagy requires PLCγ signaling, which in turn activates 
JNK1 via PKCδ. Finally we found that, in primary human keratinocytes derived 
from light or dark pigmented skin and expressing different levels of FGFR2b, the 
rate of phagocytosis and autophagy and the convergence of the two intracellular 
pathways depend on the level of receptor expression. These results suggest that 
FGFR2b signaling would control in vivo the number of melanosomes in 
keratinocytes, determining skin pigmentation. 
Since the early oncoprotein E5 of the human papillomavirus type 16 (16E5) is 
able to down-regulate FGFR2b expression and since it has been recently proposed 
a possible role of the entire “early protein pool” of HPV16 in inhibiting the 
autophagic process in epithelial cells, I also proposed to investigate the possible 
impairment of FGFR2b-induced autophagy in keratinocytes expressing 16E5. The 
results showed that the presence of 16E5 strongly inhibited the autophagic 
process, while forced expression and activation of FGFR2b counteracted this 
effect, demonstrating that the viral protein and the receptor exert opposite and 
interplaying roles not only on epithelial differentiation, but also in the control of 
autophagy. In W12 cells, silencing of the 16E5 gene in the context of the viral full 
length genome confirmed its role on autophagy inhibition. Finally, molecular 
approaches showed that the viral protein interferes with the transcriptional 
regulation of autophagy also through the impairment of p53 function, indicating 
that 16E5 uses parallel mechanisms for autophagy impairment. Overall our results 
further support the hypothesis that a transcriptional crosstalk among 16E5 and 
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FGFR2b might be the crucial molecular driver of epithelial deregulation during 
early steps of HPV infection and transformation.  
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Autophagy 
 
Autophagy is a lysosomal degradative pathway conserved from yeast to 
mammalians, used by the cells to eliminate or recycle cytoplasmic components, 
such as damaged organelles, membranes and molecules, to maintain cellular 
homeostasis or to adapt the cells to stress conditions (Feng et al., 2014). There are 
three forms of autophagy: macroautophagy, microautophagy and chaperone-
mediated autophagy. In macroautophagy substrates are sequestered in a double-
membrane structure called autophagosome. This organelle then fuses with 
lysosome promoting the degradation of its inner membrane and the engulfed 
material by lysosomal enzymes (Mizushima et al., 2011). The second type of 
autophagy is chaperone-mediated autophagy (CMA). In this pathway cytosolic 
proteins, marked by a pentapeptide motif with a consensus sequence similar to 
KFERQ, are recognized and selectively translocated to the lysosomal membrane 
by the chaperon protein Hsc70, which promotes the translocation into the 
lysosomal lumen through the binding to LAMP-2A. Finally, the third type is 
microautophagy, in which part of the cytoplasm is engulfed by direct invagination 
of the lysosomal membrane (Ravikumar et al., 2010; Mizushima et al., 2011). 
Macroautophagy, commonly called autophagy, is the most extensively 
studied membrane pathway, which is present at basal level and plays an 
important role in maintaining cellular homeostasis. However, this process can be 
up-regulated as a citoprotective response by several stimuli such as nutrient 
starvation (glucose or amino-acid withdrawal), hypoxia, oxidative stress, 
pathogen infection, radiation and anticancer drug treatment (Yang and Klionsky, 
2010).  Macroautophagy can be also a selective process to target specific damaged 
organelles, such as mitochondria (mitophagy) and peroxisomes (pexophagy) 
(Deffieu et al., J Biol Chem 2009; Dunn et al., Autophagy 2005), or invasive 
pathogens (xenophagy) (Levine et al., Nature 2011) to the lysosomal compartment  
(Figure 1).  
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The autophagic machinery 
 
The autophagic machinery consists of about 40 autophagy-related genes 
(ATGs) first identified in yeast. Many of these genes have orthologs in 
mammalians, although they present important differences in biology and 
architecture, and they have been defined as the core autophagy genes, mainly 
involved in autophagosome biogenesis (Lamb et al., 2013; Bento et al., 2016).  
The process which leads to the formation of a mature autophagosome can be 
divided in three step: the initiation, which consists in the transmission of the 
signal to the membrane source involved in the nucleation of the isolation 
membrane, with consequent recruitment of the initiating complexes; the 
nucleation, that leads to the formation of the isolation membrane from the 
membrane source; the expansion, where the isolation membrane expands until 
close completely, forming the autophagosome (Mizushima et al., 2011; Lamb et al., 
2013; Feng et al., 2014).  
The first complex involved in the stage of initiation is the ULK1/2.  ULK1/2 
is formed by UNC51 like Ser/Thr kinases ULK1/2, ATG13, FAK family kinase-
interacting protein of 200 kDa (FIP200) and ATG101. ULK1/2 interact with 
ATG13, which directly binds FIP200 leading to its interaction with the ULKs 
(Hosokawa et al., 2009; Jung et al., 2009). The ULK1/2 complex can be 
activated/phosphorylated (Ser317 and Ser777) by an AMP-activated protein 
kinase (AMPK)-dependent (autophagy induced by glucose starvation) or AMPK-
independent (autophagy induced by amino acid starvation) pathway (see below). 
Under fed conditions the ULK1/2 complex is inhibited by the binding with 
mTORC1, the key upstream negative regulator of autophagy, which 
phosphorylates/inactivate ULK1/2 (Ser757). On the contrary, upon nutrient 
starvation mTORC1 is released from the complex with consequent ULK1/2 
activation (Kim et al., 2011). 
Another important complex required for the initiation step of autophagosome 
formation is the class III phosphatidylinositol (PI) 3-kinase (PI3K) complex (also 
known as the Beclin 1 complex), which consists of vacuolar protein sorting 34 
(Vps34, also known as the PI3K catalytic subunit 3), p150, Beclin 1 and ATG14 
subunits and it is necessary for the generation of phosphatidylinositol 3-phosphate 
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(PI3P) (Mizushima et al., 2011). Beclin 1 is a key protein of the PI3K complex since 
it interacts with Vps34 and enhances its activity. Many other proteins can interact 
with Beclin 1 and positively regulate autophagy, such as AMBRA1, Bif-1 and 
vacuole membrane protein 1 (VMP1), while BCL-2 inhibits autophagy by 
sequestering Beclin 1 from the PI3K complex (Funderburk et al., 2010). 
During the nucleation step the activated ULK1/2 and the PI3K complexes 
are recruited to the membrane site of autophagosome initiation. Here the ULK1/2 
complex can phosphorylate different proteins at Ser and Thr residues, among 
which Beclin 1 and its interacting protein AMBRA1, which in turn enhance the 
activity of the PI3K complex (Di Bartolomeo et al., 2010; Russell et al., 2013). The 
PI3K complex generates a pool of PI3P in the membrane, necessary for the 
recruitment of other ATG proteins or autophagy-specific PtdIns(3)P effectors, such 
as double FYVE-containing protein 1 (DFCP1) and WD-repeat domain 
phosphoinositide-interacting (WIPI) proteins.  
In the last stage of autophagosome formation, the elongation, two 
ubiquitin-like proteins are involved in the autophagosome membrane expansion 
and closure: ATG12 and LC3. ATG12 is conjugated to ATG5 through a mechanism 
that requires ATG7, an E1-like enzyme, and ATG10, an E2-like enzyme 
(Mizushima et al., 1998). The ATG12-ATG5 complex then interacts with ATG16L1, 
forming the ATG12-ATG5-ATG16L1 complex, which is recruited to the outer side 
of the isolation membrane.  In parallel cytosolic LC3 is cleaved in the C-terminal 
by the cysteine protease ATG4, leaving a glycine residue, which is following 
activated by ATG7. Finally, the E2-like enzyme ATG3 and the ATG12-ATG5-
ATG16L1 complex promote	 the conjugation of LC3 to the 
phosphatidylethanolamine (PE), generating lipidated LC3 (LC3-II), which 
associates to the autophagosomal membrane (Kabeya et al., 2004; Sakoh-
Nakatogawa et al., 2013). ATG12-ATG5-ATG16L1 complex is released upon the 
autophagosome closure (Mizushima et al. 2001), while the LC3-II localized in the 
inner membrane of the autophagosome is retained (Kabeya et al., 2004). Recent 
evidences have shown also a role for actin filaments in autophagosome shaping. 
During the nucleation step, the actin-capping protein (CapZ) binds to PI3P and 
stimulates actin polymerization and branching, in the inner face of the isolation 
membrane (Aguilera et al., 2012; Mi et al., 2015). These evidences strongly suggest 
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a new important role for actin in the autophagosome biogenesis.  
 
 
Sources of autophagosome membranes 
 
 Even if a role for various organelles has been proposed as the membrane source 
of autophagosomes, such as the endoplasmic reticulum (ER), the Golgi complex, 
mitochondria, endosomes and plasma membrane (Figure 1), the origin of the 
autophagosomal membrane remains still unclear. Among the different possible 
membrane sources, the ER seems to be the best candidate, while the other 
organelles may contribute to the autophagosomal membrane expansion during 
the elongation step (Lamb et al., 2013; Ktistakis and Tooze, 2016; Bento et al., 
2016).  
            The autophagosome originates from a preexisting membrane called 
isolation membrane, which appears to emerge from an omega-shaped subdomain 
of the ER (the omegasome) (Hayashi-Nishino et al., 2009).  The ULK1/2 and the 
PI3K complexes are recruited in the omegasome, sustaining the expansion of the 
isolation membrane, until it reaches a sufficient size to allow ULK1/2 complex 
dissociation (Lamb et al., 2013). During the nucleation step the interaction between 
Beclin 1, a member of the PI3K complex, and the vacuole membrane protein 1 
(VMP1), which is a multispanning transmembrane protein localized in the ER and 
in the Golgi, is required at the level of the omegasome (Molejon et al., 2013). In 
addition, during this stage the PtdIns(3)P-binding protein DFCP1 is mobilized 
from the Golgi to ER and partially co-localizes with the autophagic markers LC3 
and ATG5 (Axe et al., 2008), while the PtdIns(3)P effector WIPI localizes in the 
omegasome and is required for the recruitment of the ATG12-ATG5-ATG16L1 
complex binding ATG16L1 (Dooley et al., 2014), which then conjugates LC3-PE to 
the autophagosome membrane (see above).  
Others membrane sources seem to be required for autophagosome 
formation like mitochondria and particularly the outer membrane of these 
organelles. In fact, during serum-starved induced autophagy ATG5 and LC3 
colocalize with mitochondria, and their membranes seem to be in contact with the 
autophagosome membranes (Hailey et al., 2010).  
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Moreover, another theory about the autophagosome biogenesis proposes 
the ER-mitochondria contact site as a candidate in this process, since ATG14 and 
ATG5 were found localized in this site (Hamasaki et al., 2013).  
The Golgi complex and endosomes also can participate to autophagosome 
expansion, possibly providing ATG9-positive vesicle. ATG9 is a transmembrane 
protein, which resides on the trans-Golgi network (TGN) and in the endosomal 
compartments but is mainly localized in endosomes during nutrient deprivation. 
The ULK complex regulates its distribution and the vesicles containing ATG9 
participate to the expansion of the isolation membrane (Orsi et al., 2012; Puri et al., 
2014). In addition, the recycling endosomes represent an alternative source for 
autophagosome formation, as suggested by the evidence of direct interaction 
between the PX-BAR protein SNX18 and ATG16L1 and LC3 at the level of the 
recycling endosome membranes (Knaevelsrud et al., 2013).   
Moreover, the ER-Golgi intermediate compartment (ERGIC) is gaining an 
emerging role as a membrane source for autophagosome, indicated by the serum 
deprivation–induced budding of LC3-II positive vesicles from this compartment, 
which contribute to the expansion of the autophagosomal isolation membrane (Ge 
et al., 2013; Ge et al., 2014).  
The plasma membrane can also contribute to autophagosome formation 
since some clathrin-coated vesicles (CCV) derived from this compartment are 
ATG16L1-positive and subsequently acquire LC3 and reach the omegasome 
(Ravikumar et al., 2010; Moreau et al., 2011). 
 
 
Noncanonical autophagy 
 
Many studies have revealed the presence of a noncanonical autophagy. This 
definition includes an autophagosome formation in which some key ATG proteins 
and/or complexes are lost or alternative processes in which ATG proteins are 
recruited to single membrane structures involved in either lysosomal degradation 
or nondegradative functions (Juenemann and Reits, 2012; Ktistakis and Tooze, 
2016). The ATG5/Atg7-independent pathway, possibly involved in the 
elimination of mitochondria in reticulocytes, was first discovered in mouse 
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embryonic fibroblasts (MEF) and consists in autophagic vesicle formation in 
response to autophagic stimuli, which requires ULK1/2 and Beclin 1 complexes 
recruitment, but not the LC3 lipidation/association (Nishida et al., 2009; Honda et 
al., 2014). Moreover, a noncanonical autophagy requiring ATG7 activity for LC3-I 
lipidation, but not Beclin 1 and Vps34 activation, has been described in 
mammalian neurons treated with the neurotoxic agent 1-metil-4-
phenylpyridinium  (Zhu et al., 2007).  
Very recently, increased evidences have proposed that some ATG proteins 
could be recruited to the surface of different single membrane compartments to 
promote their convergence to lysosomes (Pimentel-Muin ̃os and Boada-Romero, 
2014; Ktistakis and Tooze, 2016). This is the case of the LC3-associated 
phagocytosis (LAP), occurring in macrophages after toll-like receptor activation, 
in which Beclin 1 and LC3 are recruited on the phagosome membranes to facilitate 
their fusion with lysosomes (Sanjuan et al., 2007). In alternative, the recruitment of 
autophagic proteins on the membrane of compartments different from 
autophagosomes can be required to also promote nondegradative functions 
(Pimentel-Muin ̃os and Boada-Romero, 2014). This is the case of some stable LC3-
II-positive phagosomes, compartments that promote the survival and replication 
of pathogens, such as bacteria, rather than induce their degradation (Figure 2). 
According to this more general role for the autophagic machinery in the 
regulation of nondegradative processes, it has been proposed for various ATG 
proteins also a role in the secretion pathways (Pimentel-Muin ̃os and Boada-
Romero, 2014). For instance, in melanocytes the autophagosomal markers ATG5 
and LC3 appear localized on the single membrane of melanosomes, possibly 
promoting their maturation and secretion (Ganesan et al., 2008). A similar 
mechanism appears to be also involved in the secretion of IL1B (Dupont et al., 
2011), or in that of the secretory granules in PC12 cell line (Figure 2) (Ishibashi et 
al., 2012). These last recent findings sustain the importance of the autophagic 
machinery in nondegradative biological functions.  
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Intracellular signaling pathways involved in autophagy  
 
 
Various signaling pathways can control the autophagic process and the 
main activated upon several autophagic stimuli, like serum deprivation, hypoxia 
or stress conditions, is the mTOR pathway (Ravikumar et al., 2010; Russel et al., 
2014). mTOR (mammalian target of rapamycin)  is a serine/threonine kinase, 
which can form two different complexes, mTORC1 and mTORC2, among which 
only the mTORC1 complex is involved in autophagy regulation (Jewell et al., 
2013). mTORC1 complex consists of five subunits: TOR, RAPTOR (regulatory-
associated protein of mTOR), mLST8 (mammalian lethal with SEC13 protein), 
DEPTOR (DEP domain-containing mTOR-interacting protein) and PRAS40 (40 
kDa Pro-rich AKT substrate) (Laplante  et al., 2012). Under nutrient-rich 
conditions mTORC1 is active and associated to lysosomes. In these conditions, the 
Ragulator complex, which acts as a guanine nucleotide exchange factor (GEF), 
activates and recruits the RAG GTPases on the lysosomal surface (Sancak et al., 
2010), which in turn binds the mTORC1 complex at the lysosomal membrane (Kim 
et al., 2008; Sancak et al., 2008). Here mTORC1 is activated by the small GTPase 
Rheb (Garami et al., 2003; Inoki et al., 2003; Tee et al., 2003). During growth factors 
stimulation, the main pathway involved in Rheb-mediated activation of mTORC1 
is the PI3K/AKT pathway, (Inok et al., 2002; Potter et al., 2002). Thus, mTORC1 
activation under fed conditions and growth factor stimulation acts as a powerful 
inhibitor of the autophagic process. In fact, active mTORC1 is able to inhibit the 
two autophagic complexes involved in autophagy initiation, ULK1/2 complex 
and PI3K complex (Russel et al., 2014). In fact, mTORC1 inhibits the PI3K complex 
inducing ATG14 phosphorylation (Yuan et al., 2013) and it can directly 
phosphorylate ATG13 and ULK1 in Ser757 inhibiting their kinase activity. Under 
nutrient starvation or treatment with the mTOR inhibitor, rapamycin, mTORC1 is 
released from ULK1/2 complex leading to its activation and autophagy initiation 
(Ganley et al., 2009; Hosokawa et al., 2009; Jung et al., 2009).  
 Another way to inhibit mTORC1 and induce the autophagic process is via 
AMPK. AMPK is a serine/threonine kinase, which is activated by AMP or ADP 
and therefore by low ATP levels. In these conditions AMPK inhibits mTORC1 by 
the activation of TSC, a complex involved in the release of mTORC1 from 
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lysosomes and consequently in its inhibition. AMPK can also directly inhibit 
mTORC1 via its phosphorylation (Gwinn et al., 2008). Alternatively, AMPK can 
directly activate ULK1, inducing its phosphorylation on Ser317 and Ser777 (Kim et 
al., 2011; Bach et al., 2011), or Vps34, through Beclin 1 phosphorylation on Ser91 
and Ser94 (Kim et al., 2013). 
Other kinases can regulate autophagy, such as the mitogen-activated 
protein kinase (MAPK)/extra-cellular signal-regulated kinase (ERK) pathway. In 
fact, this pathway is activated during starvation-induced autophagy and its 
inhibition, through the use of a MEK1/2 inhibitor, affects autophagy in the HT-29 
cell line (Ogier-Denis et al., 2000). Upon serum deprivation AMPK induces a 
transient activation/phosphorylation of MAPK/ERK pathway, which promotes 
increased expression of Beclin 1, mTORC1 disassembly and consequently 
autophagy as cytoprotective mechanism. However, sustained MEK/ERK 
activation leads to a destructive autophagy, which results in cell death (Wang et 
al., 2009).  
Serum deprivation also activates autophagy via c-Jun N-terminal protein 
kinase 1 (JNK1), which phosphorylates BCL-2 and allows the release of Beclin 1 
from the autophagic inhibitor complex BCL-2/Beclin 1 (Wei et al., 2008).  
 
 
Fibroblast growth factor receptors: receptor-mediated signaling pathways 
involved in the regulation of autophagy 
 
The fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases 
(RTKs) belonging to a family composed by four highly conserved transmembrane 
tyrosine kinase receptors (FGFR1, FGFR2, FGFR3 and FGFR4) encoded by four 
different genes. FGFRs are activated by fibroblast growth factor (FGF) family 
members, which is composed by 18 members clustered in five paracrine 
subfamilies and one endocrine subfamily. FGFRs are expressed on different 
tissues and regulate many key cellular physiological processes, such as 
proliferation, differentiation, migration and survival (Turner and Grose, 2010; 
Goetz and Mohammadi, 2013). FGFRs consist of an extracellular domain, a single-
pass transmembrane domain and an intracellular tyrosine kinase domain (Figure 
	 13	
3). The extracellular domain is composed by three immunoglobulin (Ig) like 
domains (I-III), an “acid box” between domains I and II characterized by an acidic, 
serine-rich region and a conserved positively charged binding site for heparin 
(Schlessinger et al., 2000). The first Ig-like domain, together with the acid box, 
seem to be involved in receptor autoinhibition (Olsen et al., 2004), while the 
second and third Ig-like domains form the binding site for FGF ligands 
(Mohammadi et al., 2005). The ligand binding specificity by FGFR1, FGFR2 and 
FGFR3 is determined by the alternative splicing of the third Ig-like domain of 
these receptors, which generates FGFRb and FGFRc isoforms (Figure 3). In 
particular, for FGFR2 the N-terminal portion of the Ig-III domain is encoded by 
the exon 7 (exon IIIa), while the C-terminal portion is encoded alternatively by 
exon 8 (exon IIIb), and 9 (exon IIIc), which determines respectively FGFR2IIIb and 
FGFR2IIIc isoforms with different ligand-binding specificities; in fact, while 
FGFR2IIIb specifically binds FGF7/KGF (Rubin et al., 1989) and FGF10 (Igarashi et 
al., 1998), FGFR2IIIc binds FGF2 (Yayon et al., 1992) (Figure 4). The alternative 
splicing also determines the tissue specificity of the FGFRs; in fact the FGFR2IIIb 
isoform is exclusively expressed in epithelial cells, while the FGFR2IIIc isoform is 
expressed exclusively in mesenchymal cells (Miki et al., 1992; Orr-Urtreger et al., 
1993). FGFs binding to FGFRs induces receptor dimerization and the juxtaposition 
of the two intracellular kinase domains of the two receptors inducing the 
phosphorylation of each other (Goetz and Mohammadi, 2013). However, FGF-
FGFR binding requires the presence of a cofactor, heparan sulphate proteoglycan 
(HPSG), which is present in the cell plasma membrane and stabilizes the 
interaction between FGF and FGFR enhancing resistance to proteolysis and 
forming a dimeric 2:2:2 FGF-FGFR-HSPG ternary complex on the cell surface 
(Schlessinger et al., 2000).  
 
FGF/FGFR interaction induces receptor dimerization, which leads to a 
conformational change in receptor structure inducing the activation of the 
intracellular kinase domain, which in turn triggers the intermolecular 
transphosphorylation of the tyrosine kinase domain and the carboxy-terminal tail 
(Turner and Grose, 2010; Brooks et al., 2012). Several tyrosine residues of the 
receptor can be autophosphorylated and for FGFR1 have been identified seven 
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residues (Y463, Y583, Y585, Y653, Y654, Y730, and Y766) (Lew et al., 2009). Once 
phosphorylated these residues act as docking sites for adaptor proteins, which are 
recruited and phosphorylated by FGFRs leading to activation of several signaling 
pathways (Figure 5) (Turner and Grose, 2010). The main downstream substrates of 
FGFRs are the FGFR substrate 2 (FRS2) and the phospholipase Cγ (PLCγ). FRS2 
family is composed by two members, FRS2α and FRS2β (Gotoh et al., 2008), which 
both contain a consensus myristylation sequence at the N-terminus for binding to 
lipids in the plasma membrane (Gotoh et al., 2008) and a phosphotyrosine binding 
(PTB) domain and multiple tyrosine phosphorylation sites at the C-terminus, 
which need to bind RTKs. FRS2 proteins can bind a limited specie of RTKs, such 
as neurotrophin receptors, RET and ALK, but in particular FGFRs and FRS2α acts 
as the major mediator of intracellular signaling via FGFRs. The PTB domains of 
FRS2 proteins bind constitutively to unphosphorylated peptides at the 
juxtamembrane domain of the FGFR. The activation of FGFRs induces FRS2 
phosphorylation on several sites creating docking sites for additional adaptor 
proteins. In fact, FRS2α contains four tyrosine phosphorylation sites that bind the 
adaptor protein growth-factor-receptor-bound protein 2 (Grb2) and two binding 
sites for the SH2-containing tyrosine phosphatase protein (Shp2). Grb2 can bind 
many proteins via two SH3 domains, such as Gab1, SOS and Cbl. The recruitment 
of Gab1 by Grb2 forms a ternary complex with FRS2α, which in turn induces the 
recruitment of PI-3 kinase and the activation of PI3K/AKT pathway (Figure 5) 
(Altomare et al., 2005). Sos is a guanine nucleotide exchange factor (GEF), which 
can activate Ras; therefore the recruitment of Grb2-Sos on FGFR induced by FRS2α 
activation triggers Ras/mitogen-activated protein kinase (MAP kinase) pathway 
activation (Figure 5) (Eswarakumar et al., 2005). The binding of Shp2 to FRS2α 
induces tyrosine phosphorylation of Shp2, which in turn induces a strong 
activation of ERK, a component of MAP kinases family, in response to FGF 
stimulation (Hadari et al., 1998). The activation of ERK induced by growth factors 
can be transient or sustained (Marshall 1995). In the transient phase, the growth 
factors-induced activation of ERK picks within 5 minutes and returns to basal 
levels within 1 hour while in the sustained phase is maintained for several hours 
and reduces gradually. FRS2α activation induced by FGF stimulation can triggers 
both transient and sustained activation of ERK by either its shp2-binding and 
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Grb2-binding sites even if they induce a strong and moderate activation of ERK 
respectively (Hadari et al., 2001). Another important signaling activated by 
FGF/FGFR binding, independent from FRS2, is the PLCγ pathway (Figure 5). This 
phospholipase binds through its Src homology 2 (SH2) domain to a 
phosphotyrosine residue in the C-terminal receptor tail, inducing PLCγ 
phosphorylation and activation. Particularly, it has been demonstrated that the 
tyrosine 766 residue in the C-terminal of FGFR1 is required for PLCγ protein 
binding (Mohammadi et al., 1991), which corresponds to tyrosine 769 in FGFR2b 
(Ceridono et al., 2005; Cha et al., 2009). PLCγ activation induces 
phosphatidylinositol-4,5-biphosphate (PIP2) hydrolysis in phosphatidylinositol-
3,4,5-triphosphate (PIP3) and diacylglycerol (DAG), that in turn activates the 
members of the serine-threonine kinases family protein kinase C (PKC), which 
contribute to MAPK pathway activation by phosphorylating Raf (Brooks et al., 
2012) . In addition, several other pathways can be activated by FGFRs, such as 
signal transducer and activator of transcription (STAT) signaling, ribosomal 
protein S6 kinase 2 (RSK2), the p38 MAPK and Jun N-terminal kinase pathways 
(Touat et al., 2015), which can be activated downstream RAS by the MAPKKs, 
MKK4 and MKK7 (Katz et al., 2007) but also via PKCδ (Liu et al., 2006; Chen et al., 
2008). 
FGFR signaling is regulated by several factors that exert negative feedback 
control on many elements of the FGFR cascade. In fact, after receptor activation it 
is internalized and degraded or recycled through a Cbl-mediated 
monoubiquitylation. Cbl is an E3 ubiquitin ligase, which forms a ternary complex 
with FRS2α and Grb2, inducing ubiquitination and degradation of FRS2α and the 
sorting of the receptor to the endocytic lysosomal degradative pathway (Turner 
and Grose, 2010). The MAPK signaling, in particular ERK1 and ERK2, can 
phosphorylate FRS2 on many serine/threonine residues blocking Grb2 
recruitment. In addition, the downstream signaling of FGFR can be attenuated by 
several negative regulators, such as the MAPK phosphatase 1 and 3 (MKP1 and 
MKP3), that dephosphorylate ERK1 and ERK2, Sprouty (SPRY) proteins, that 
compete for Grb2 biding with Sos preventing RAS activation or directly bind RAF 
blocking MAPK signaling, the Similar Expression to FGF (SEF) family members, 
which can interact with FGFRs and compete for substrate binding or cause 
	 16	
receptor dephosphorylation and FGFRL1 that modulates ligand binding (Figure 5) 
(Turner and Grose, 2010).  
 
Several growth factors/receptor tyrosine kinases (RTKs) signaling pathways, 
including those activated by FGF/FGFRs can exert a regulatory control on the 
autophagic process. In particular, insulin-like growth factor-1 (IGF1) (Sobolewska 
et al., 2009) as well as platelet-derived growth factor (PDGF)  (Takeuchi et al., 
2004), negatively regulate autophagy through the activation of the 
PI3K/AKT/mTOR pathway. More recently it has been described that PDGF is 
able to induce autophagy in vascular smooth muscle cells (VSMCs) via a 
PI3K/AKT/mTOR-independent pathway (Salabei et al., 2013). In addition, an 
inhibitor role on autophagy through a canonical mTOR-dependent mechanism 
has been demonstrated also for the epidermal growth factor (EGF) (Sobolewska et 
al., 2009). More recently an additional mTOR-independent inhibitory mechanism 
on autophagy, which directly involves Beclin 1 phosphorylation/inhibition, has 
been described for EGF/EGFR (Wei et al., 2013). More interestingly, a recent study 
demonstrated that the inactive form of EGFR is able to trigger autophagy, through 
a mTORC1-independent mechanism; this inactive receptor interacts with Rubicon, 
a Beclin 1 inhibitor, inducing Beclin 1 release from Beclin 1/Rubicon complex and 
its consequent activation (Tan et al., 2015).   
Several evidences have proposed contrasting roles for FGFRs on autophagy 
regulation. In fact, previously studies have demonstrated that in mouse fibroblasts 
the fibroblast growth factor 2 (FGF2)-mediated activation of the fibroblast growth 
factor receptor 1/2 (FGFR1/2) inhibits autophagy, and in particular the 
autophagosome assembly, through the activation of the PI3K/AKT/mTOR 
pathway (Lin et al., 2011). This inhibitory role exerted by FGF2 is required to 
prevent premature differentiation of cardiac progenitor cells (Zhang et al., 2012), 
as well as to induce a protective effect in myocardial ischemia/reperfusion (Wang 
et al., 2015) or to maintain the proliferative potential of the mesenchymal stem 
cells (Eom et al., 2014). Recently it has been also demonstrated that FGF2-mediated 
activation of FGFR3 inhibits autophagy in chondrocytes inducing a decrease 
protein expression of the ATG12-ATG5 complex, which in turn induces a 
suppression of the cartilage development. This phenomenon plays a key role in 
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achondroplasia pathogenesis (Wang et al., 2015). Interestingly in the same context 
of chondrocytes it has been very recently shown that FGF18-induced activation of 
FGFR4 triggers autophagy via a JNK1-mediated, mTOR-independent pathway, 
which is required for bone growth (Cinque et al., 2015).  
Finally, our previous studies have demonstrated that the activation of 
FGFR2b by FGF7 induces autophagy in human keratinocytes through a PI3K-
AKT-mTOR-independent signaling, which is required to stimulate the 
autophagosome assembly (Belleudi et al., 2014). However, the molecular 
mechanism involved in FGFR2b-triggered autophagy is still to be elucidated (see 
below). 
 
 
The fibroblast growth factor receptor 2b and its signaling in the control of 
autophagy in human keratinocytes 
 
The epithelial splicing transcript variant of the fibroblast growth factor 
receptor 2 (FGFR2b/KGFR) can be activated by the stimulation with the specific 
paracrine ligand FGF7 (see above), which is secreted by dermal fibroblasts. 
FGFR2b expression and signaling regulate different processes, including cell 
migration (Ceccarelli et al., 2007; Belleudi et al., 2011), differentiation (Belleudi et 
al., 2011; Purpura et al., 2013) and phagocytosis (Cardinali et al., 2005; Cardinali et 
al., 2008; Belleudi et al., 2011) in human keratinocytes.  
The possible role of FGFR2b in the regulation of epidermal differentiation 
has been suggested in the past by several evidences. In fact, it has been observed 
that FGFR2b is mainly expressed in the spinous suprabasal layer of epidermis (La 
Rochelle et al., 1995; Marchese et al., 1995) and this receptor is up-regulated in the 
suprabasal keratinocytes compared to the basal cells (Marchese et al., 1997; 
Capone et al., 2000). More recently it has been demonstrated that FGFR2b induces 
early differentiation in keratinocytes during the switch from basal undifferentiated 
to suprabasal differentiating cells (Belleudi et al., 2011). The ligand-dependent 
activation and signaling of FGFR2b are required for the receptor ability to induce 
the early differentiation and using specific inhibitors of FGFR2b substrates, we 
demonstrated that the PI3K/AKT signaling pathway is the main involved in the 
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regulation of this process (Belleudi et al., 2011). The key role of FGFR2b in the 
regulation of early steps of keratinocyte differentiation has been also 
demonstrated by the evidence that the oncoprotein E5 of the human 
papillomavirus type 16 (HPV16) is able to impair this process (Purpura et al., 
2013) also through a transcriptional and post-translational down-regulation of 
FGFR2b (Belleudi et al., 2011; Purpura et al., 2013).  
Another important process regulated by FGFR2b is the phagocytosis, a key 
process used by the cells for the ingestion of particles larger than 0.5 µm into 
single membrane compartments called phagosomes (Freeman and Grinstein, 
2014). Phagocytosis particularly occurs in professional phagocytes, such as 
macrophages, dendritic cells and neutrophils (Freeman and Grinstein, 2014), but it 
can be triggered also in other cell types and, in particular, in epidermal 
keratinocytes this process is used for melanosome uptake. Melanosomes are large 
(0.5 µm) lysosomal-related organelles containing synthesized melanin, which are 
released by the neighboring melanocytes and are engulfed by keratinocytes to 
regulate photoprotection and pigmentation (Boissy et al., 2003; Van Den Bossche 
et al., 2006; Wasmeier et al., 2008). It has been previously demonstrated that FGF7-
induced FGFR2b activation induces phagocytosis and consequently melanosome 
uptake in human keratinocytes (Cardinali et al., 2005; Cardinali et al., 2008; 
Belleudi et al., 2011). In addition, using a FGFR2b signaling mutant in which the 
tyrosine 769 required for PLCγ  binding and activation (Ceridono et al., 2005; Cha 
et al., 2009) has been substituted by phenylalanine (Y769F) (Ceridoni et al., 2005), 
we demonstrated that	PLCγ-mediated signaling is required for FGFR2b-triggered 
phagocytosis.  
Even more recently a role of FGFR2b and its FGF7-induced signaling in the 
control of autophagy in human keratinocytes has been highlighted by us. Unlike 
other growth factors and similarly to FGF18 in chondrocytes, FGF7 and 
consequently its receptor activation triggers autophagy in human keratinocytes 
(Belleudi et al., 2014). In particular, using the inhibitor of endoplasmic reticulum 
(ER) Ca2+-ATPase pump family thapsigargin (Thastrup et al., 1990) to block the 
fusion between autophagosomes and lysosomes, we demonstrated that FGF7 
triggers the early step of the autophagic process inducing the formation of new 
autophagosomes. In addition, we also found that FGF7 is also able to accelerate 
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the autophagosome fusion with lysosomes, protecting cells from their potentially 
dangerous accumulation and clustering in the cytosol (Belleudi et al., 2014). This 
last evidence is consistent with the well-known survival role of FGF7 in epithelial 
cells (Panos et al., 1995; Decraene et al., 2004; Lotti et al., 2007) and it is in 
agreement with recent evidences proposing a role for autophagy in contributing to 
skin pigmentation by regulating melanosome degradation in keratinocytes 
(Murase et al., 2013). The autophagic activity and consequently the melanosome 
degradation appeared to be higher in keratinocytes derived from light skin 
compared to those detected in keratinocytes from dark skin (Murase et al., 2013).  
More interestingly we found an important link between autophagy and 
epidermal commitment to differentiation, demonstrating that FGF7-triggered 
autophagy is required for FGFR2b-induced early differentiation (Belleudi et al., 
2014). The involvement of autophagy in cell differentiation may be explained by 
the fact that this degradative pathway could play a key role in mediating rapid 
proteins and organelles turnover which might be required for the rapid change of 
cell phenotype during differentiation (Cecconi et al., 2008; Di Bartolomeo et al., 
2010). The differentiation program is essential to maintain tissue homeostasis and 
to promote keratinocyte regeneration through terminal differentiation, which 
involves cell organelle clearance, mediated in part by lysosomal degradation (Li et 
al., 2016). Starting from this hypothesis, a close interplay between differentiation 
and autophagy has been proposed in many cell types, including keratinocytes 
(Haruna et al., 2008; Aymard et al., 2011; Chatterjea et al., 2011; Moriyama et al., 
2014 ; Belleudi et al., 2014, Chikh et al., 2014; Akinduro et al., 2016). In fact, 
autophagy seems to be required for epidermal terminal differentiation, as shown 
by the higher concentration of the autophagic marker LC3 in the granular layer 
(Haruna et al., 2008; Moriyama et al., 2014, Akinduro et al., 2016). However, other 
evidences indicated a role for this process even in the early stages of keratinocyte 
differentiation. In fact, the expression of LC3 is evident already in the suprabasal 
layer of the epidermis (Haruna et al., 2008) and it increases in parallel with the 
early differentiation markers keratin 1 (K1) and keratin 10 (K10) (Haruna et al., 
2008; Belleudi et al., 2014; Chikh et al., 2014). In addition, K1 and K10 expression is 
repressed by the inhibition of autophagy in differentiating keratinocytes (Belleudi 
et al., 2014; Chikh et al., 2014). In addition, the autophagic markers, ATG5-ATG12 
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and Beclin 1, are expressed at high levels in the basal layer (Akinduro et al., 2016). 
Moreover, BCL2 and the adenovirus E1B 19-kDa-interacting protein 3 (BNIP3), a 
pro-apoptotic BH3-only protein, is able to promote keratinocyte differentiation 
inducing autophagy (Moriyama et al., 2014), while the expression of the protein 
iASPP, a p53 inhibitor, delays keratinocyte differentiation through the inhibition 
of autophagy (Chikh et al., 2014). iASPP is involved in a double positive loop with 
transcription factor ΔNp63α, which is expressed in the basal cells of stratified 
epithelia such as human epidermis (Candi et al., 2008) and it is required for 
keratinocytes differentiation (Truong et al., 2006; Candi et al., 2008).  Therefore, the 
positive loop between iASPP and ΔNp63α plays a crucial role in epidermal 
homeostasis, and iASPP down-regulation is a key event determining autophagy 
induction, ΔNp63α repression and consequently induction of differentiation 
(Chikh et al., 2011; Chikh et al., 2014). 
Autophagy is not only a degradative pathway correlated to cell 
differentiation, but it is also an interplaying process with phagocytosis at least in 
macrophages. In fact, it has been demonstrated that autophagy induction 
promotes the engulfment of phagosomes containing bacteria in autophagosomes 
to allow pathogen elimination (Gutierrez et al., 2004; Xu et al., 2007). Conversely, 
other studies have proposed that autophagy induction can lead to a down-
modulation of the phagocytosis of yeast particles in murine macrophages (Lima et 
al., 2011) while its inhibition can enhance this process (Bonilla et al., 2013). 
Moreover, TLR signaling can induce the recruitment of some autophagic 
components, such as LC3 or Beclin 1, on the single membrane pathogen-
containing phagosomes, without the formation of conventional autophagosome, 
in the process called LAP (LC3-associated phagocytosis) (Sanjuan et al., 2007). 
However, there are not evidences of a correlation between autophagy and 
phagocytosis in keratinocytes. Therefore, considering that these two processes are 
both regulated by FGF7-mediated activation of FGFR2b in keratinocytes, we 
proposed to investigate the existence of a possible interplay between FGF7-
induced autophagy and phagocytosis. In addition, since it has been demonstrated 
that FGFR2b-induced phagocytosis required PLCγ downstream signaling 
(Belleudi et al., 2011), while receptor-mediated autophagy is a PI3K-AKT-mTOR-
independent process (Belleudi et al., 2014) whose specific signaling pathway 
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involved remains to be elucidated, we also proposed to investigate the role of 
PLCγ signaling in FGF7-induced autophagy.  					
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MATERIALS AND METHODS 
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Cells and treatments 	
The human keratinocyte cell line HaCaT was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) plus antibiotics. HaCaT cells stably transfected with the construct pMSG 
16E5 (HaCaT pMSG E5) or with the empty vector (HaCaT pMSG) were cultured 
as reported above and were treated with 1 µM dexamethasone (Dex) for 12 h and 
24 h to induce 16E5 expression. The human cervical keratinocyte cell line W12 
initiated from a low-grade cervical lesion (Stanley et al., 1989), which retains ~100 
to 200 copies of the HPV16 episomes per cell (Pett et al., 2004; Stanley et al., 2009; 
Gray et al., 2010), was cultured as previously described (Stanley et al., 1989) and 
used at the passage 6 (W12p6). Primary cultures of human keratinocytes derived 
from healthy skin (HKs) were obtained from patients attending the Dermatology 
Unit of the Sant’Andrea Hospital of Rome; all patients were extensively informed 
and their consent for the investigation was given and collected in written form in 
accordance with guidelines approved by the management of the Sant’Andrea 
Hospital. Primary keratinocytes were maintained in Medium 154-CF (Cascade 
Biologics, Portland, OR, USA) supplemented with Human Keratinocyte Growth 
Supplement (HKGS, Cascade Biologics) plus antibiotics and Ca2+ 0,03 mM 
(CascadeBiologics Inc.). 
Cells were transiently transfected or cotransfected with pCI-neo expression 
vector containing 16E5-HA (HaCaT E5, HKs E5), human FGFR2b WT (HaCaT 
FGFR2b WT), a kinase negative mutant FGFR2b Y656F/ Y657F (HaCaT FGFR2b 
kin-), a signaling mutant FGFR2b Y769F (HaCaT FGFR2b Y769F), the empty vector 
(HaCaT pCI-neo, HKs pCI-neo), with the pEGFP-C2 expression vector containing 
LC3 (engineered by Dr. Fimia, National Institute for Infectious Diseases IRCCS ‘L. 
Spallanzani’, Rome, Italy; and kindly provided by Prof. Francesco Cecconi, Tor 
Vergata University of Rome, Italy) (HaCaT EGFP-LC3, HKs EGFP-LC3, W12 
EGFP-LC3) or with the pDest-mCherry-EGFP tandem expression vector 
containing LC3 (HaCaT mCherry-EGFP-LC3). For all transfections jetPEITM DNA 
Transfection Reagent (Polyplus-transfection, New York, NY, USA) or Fugene HD 
(Promega, Madison, WI, USA) were used according to manufacturer’s 
instructions. 
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For RNA interference and FGFR2b or 16E5 silencing, HaCaT cells were 
transfected with Bek small interfering RNA (Bek siRNA) (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) or with unrelated siRNA as a control, 
while W12p6 cells were transfected with the E5 siRNA sequence (5′-
TGGTATTACTATTGTGGATAA-3′) (Oh et al., 2009) or the control sequence (5′-
AATTCTCCGAACGTGTCACGT-3′) (Oh et al., 2009) (Qiagen, Valencia, CA, 
USA), using Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s protocol. 
For growth factor stimulation, cells were serum starved or incubated with 
FGF7 (Upstate Biotechnology, Lake Placid, NY, USA) 100 ng/ml for 24 h at 37°C. 
To inhibit AKT or ERK or JNK or PKCδ, cells were respectively incubated with the 
specific AKT inhibitor 1L-6-hydroxy-methyl-chiro- inositol 2-(R)-2-O-methyl-3-O-
octadecylcarbonate (1 µM; Calbiochem, San Diego, CA) or with the specific 
MEK1/2 inhibitor PD0325901 (1 µM; Sigma-Aldrich Inc., Saint Louis, MO, USA) or 
with the specific JNK inhibitor SP600125 (50 µM, Sigma) or with the specific PKCδ 
inhibitor rottlerin (0.5 µM; Calbiochem) for 1 h at 37 °C before treatment with 
FGF7 in the presence of each inhibitor. 
To irreversibly block the fusion between autophagosomes and lysosomes, 
HaCaT cells were incubated with bafilomycin A1 (20 nM; Sigma) for 3 h at 37 °C 
after treatment with FGF7 in the presence of the inhibitor. 
To inhibit the autophagic degradation, cells were incubated with 20 µM 
leupeptin (Sigma) for 24 h. 
To analyze the uptake of beads in keratinocytes, HKs and HaCaT cells were 
incubated with fluorescent microspheres 0.5 µm (red) in diameter (FluoSpheres 
Fluorescent Microspheres, Molecular Probes, Eugene, OR, USA) at the 
concentration of 72 x 107 particles/ml for 4 hours. To evaluate the effects of 
FGFR2b activation on the phagocytic ability, the uptake was performed in the 
presence of FGF7 100 ng/ml (Upstate Biotechnology)  
 
Immunofluorescence   	
Cells, grown on coverslips and incubated as above, were fixed with 4% 
paraformaldehyde in PBS for 30 minutes at 25°C followed by treatment with 0.1 M 
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glycine for 20 minutes at 25°C and with 0.1% Triton X-100 for additional 5 minutes 
at 25°C to allow permeabilization. Cells were then incubated for 1h at 25°C with 
the following primary antibodies: rabbit polyclonal anti-Bek (1:50 in PBS; C-17, 
Santa Cruz Biotechnology), mouse monoclonal anti-HA (1:50 in PBS; Covance, 
Berkeley, CA, USA). The primary antibodies were visualized, after appropriate 
washing with PBS, using goat anti-rabbit IgG-Texas Red (1:200 in PBS; Jackson 
Immunoresearch Laboratories, 111-075-144), goat anti-mouse IgG-Texas Red 
(1:200 in PBS; Jackson Immunoresearch Laboratories) for 30 minutes at 25°C. 
Nuclei were stained with DAPI (1:1000 in PBS; Sigma). Coverslips were finally 
mounted with mowiol for observation.  
Fluorescence signals were analyzed by scanning cells in a series of 0.5 mm 
sequential sections with an ApoTome System (Zeiss, Oberkochen, Germany); 
image analysis was then performed by the Axiovision software (Zeiss) and 3D 
reconstruction of a selection of three central optical sections was shown in each 
figure. Quantitative analysis of EGFP-LC3-positive dots per cell was performed 
analyzing 100 cells for each sample in 5 different microscopy fields from 3 
different experiments. Quantitative analysis of the bead uptake was performed by 
counting the number of internalized beads in 100 cells for each condition, 
randomly taken from 10 microscopic fields in 3 different experiments. 
Quantitative analysis of the extent of colocalization of beads with EGFP-LC3 was 
performed by the analysis of 100 cells for each sample in 5 different fields 
randomly taken from 3 independent experiments and using the KS300 3.0 Image 
Processing System (Zeiss). Results have been expressed as mean values ± standard 
errors (SE). p values were calculated using Student’s t test and significance level 
has been defined as p < 0.05. 
 
Western blot analysis 	
Cells were lysed in a buffer containing 50 mM HEPES pH 7.5, 150 mM 
NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA, supplemented 
with protease inhibitors (10 µg/ml aprotinin, 1mM PMSF, 10µg/ml leupeptin), 
and phosphatase inhibitors (1mM sodium orthovanadate, 20 mM sodium 
pyrophosphate, 0.5 M NaF). A range between 50 and 20 µg of total protein were 
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resolved under reducing conditions by 8 or 12% SDS-PAGE and transferred to 
reinforced nitrocellulose (BA-S 83, Schleider and Schuell, Keene, NH, USA). The 
membranes were blocked with 5% nonfat dry milk in PBS 0.1% Tween 20 or with 
3% BSA in PBS 0.1%Tween 20, and incubated with anti-Bek (C-17, Santa Cruz 
Biotechnology Inc.) polyclonal antibodies, anti-LC3 (MBL, Woburn, MA, USA) 
polyclonal antibodies, anti-SQSTM1 (BD Bioscience, San Jose ̀, CA, USA) 
monoclonal antibody, anti-HA (Covance) monoclonal antibody, anti-P-p44/42 
MAPK (P-ERK1/2) (Thr202/Tyr204, Cell Signaling Technology, Beverly, MA) 
polyclonal antibodies, anti-p-AKT (Ser 473, Cell Signaling) polyclonal antibodies, 
anti p-JNK (G9, Cell Signaling) monoclonal antibody, anti p-PKCδ (Tyr-155, Santa 
Cruz Biotechnology) polyclonal antibodies followed by enhanced 
chemiluminescence detection (ECL; Amersham, Alington Heights, IL). The 
membranes were rehydrated by being washed in PBS-Tween 20, stripped with 100 
mM mercaptoethanol and 2% SDS for 30 min at 55°C, and probed again with anti-
AKT (H-136, Santa Cruz Biotechnology Inc.) polyclonal antibodies, anti-p44/42 
MAPK (ERK1/2) (137F5, Cell Signaling) polyclonal antibodies, anti-JNK (Cell 
Signaling) polyclonal antibodies, anti-PKCδ (C-20, Santa Cruz Biotechnology) 
polyclonal antibodies, anti-β-actin (Sigma) monoclonal antibody or anti-α-Tubulin 
(Cell Signaling) polyclonal antibodies to estimate the protein equal loading. 
Densitometric analysis was performed using Quantity One Program (Bio-
Rad Laboratoires, Hercules, CA). Briefly, the signal intensity for each band was 
calculated and the background subtracted from experimental values. The resulting 
values from three different experiments were then normalized and expressed as 
fold increase respect to the control value.  
 
 
Transmission electron microscopy 	
HaCaT cells stimulated with FGF7 for 24 h and treated with red fluorescent 
beads for the last 4 h as above or HaCaT pMSG E5 and HaCaT pMSG cells treated 
with Dex and stimulated with FGF7 for 24 h as above were washed three times in 
PBS and fixed with 2% glutaraldehyde (Electron Microscopy Science, 16300) in 
PBS for 2 h at 4°C. Samples were postfixed with 1% osmium tetroxide in veronal 
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acetate buffer (pH 7.4) for 1 h at 25 °C, stained with uranyl acetate (5 mg/ml) for 1 
h at 25°C, dehydrated in acetone and embedded in Epon 812 (EMbed 812, Electron 
Microscopy Science). Ultrathin sections were examined unstained or poststained 
with uranyl acetate and lead hydroxide, under a Morgagni 268D transmission 
electron microscope (FEI, Hillsboro) equipped with a Mega View II charge-
coupled device camera (SIS, Soft Imaging System GmbH) and analyzed with 
AnalySIS software (SIS).  
	
Primers 	
Oligonucleotide primers for target genes and for the housekeeping gene 
were chosen with the assistance of the Oligo 5.0 computer program (National 
Biosciences, Plymouth, MN, USA) and purchased from Invitrogen. The following 
primers were used: for HPV 16E5 target gene 5′-CGCTGCTT TTGTCTGTGTCT-
3′(sense), 5′-GCGTGCATGTGTATGTATTAAAAA-3′(antisense); for BECN1 target 
gene 5′-GGATGGTGTCTCTCGCAGAT-3′(sense), 5′-TTGGCACTTTCTGTGG 
ACAT-3′(antisense); for ATG5 target gene 5′-
CAACTTGTTTCACGCTATATCAGG-3′(sense), 5′-
CACTTTGTCAGTTACCAACGTCA-3′(antisense); for ATG7 target gene 5′-
CCGTGGAATTGATGGTATCTG-3′(sense), 5′-TCATCCGATCGTCACTGCT- 
3′(antisense); for MAP1LC3B target gene 5′-CGCACCTTCGAACAAAGAG-
3′(sense), 5′-CTCACCCTTGTATCGTTCTATTATCA-3′ (antisense); for ULK1 
target gene 5′-CAGACGACTTCGTCATGGTC-3′(sense), 5′-
AGCTCCCACTGCACATCAG-3′(antisense); for ULK2 target gene 5′-
TTTAAATACAGAACGACCAATGGA-3′(sense),5′-
GGAGGTGCCAGAACACCA-3′(antisense); for ATG4a target gene 5′-
CCGTCCGTAGTCAAGT TGC-3′(sense), 5′-TCTGATCTTCATACTTGGATAAAA 
CTG-3′ (antisense); for p21 target gene: 5′-TCACTGTCTTGTACCCTTGTGC-
3′(sense), 5′-GGC GTTTGGAGTGGTAGAAA-3′(antisense); for 14–3-3 sigma target 
gene: 5′-GACACAGAGTCCGGCATTG–3′(sense), 5′-
ATGGCTCTGGGGACACAC- 3′(antisense); for the housekeeping 18S rRNA gene: 
5′-AACCAACCCGGTCAGCCCCT-3′(sense), 5′-TTCGAATGGGTCGTCGCCGC-
3′(antisense). For each primer pair, we performed no-template control and no- 
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reverse-transcriptase control (RT negative) assays, which produced negligible 
signals. 
 
RNA extraction and cDNA synthesis 	
RNA was extracted using the TRIzol method (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instructions and eluted with 0,1% 
diethylpyrocarbonate (DEPC)-treated water. Each sample was treated with 
DNAase I (Invitrogen). Total RNA concentration was quantitated by 
spectrophotometry. 1 µg of total RNA was used to reverse transcription using 
iScriptTM cDNA synthesis kit (Bio-Rad Laboratories) according to manufacturer’s 
instructions. 
 
PCR amplification and real-time quantitation 	
Real-time PCR was performed using the iCycler Real-Time Detection 
System (iQ5 Bio-Rad) with optimized PCR conditions. The reaction was carried 
out in 96-well plate using iQ SYBR Green Supermix (Bio-Rad) adding forward and 
reverse primers for each gene and 1µl of diluted template cDNA to a final reaction 
volume of 15 µl. All assays included a negative control and were replicated three 
times. The thermal cycling programme was performed as follows: an initial 
denaturation step at 95°C for 3 minutes, followed by 45 cycles at 95°C for 10 
seconds and 60°C for 30 seconds. Real-time quantitation was performed with the 
help of the iCycler IQ optical system software version 3.0a (BioRad), according to 
the manufacturer’s manual. The relative expression of the housekeeping gene was 
used for standardizing the reaction. The comparative threshold cycle (Ct) method 
was applied to calculate the fold changes of expression compared to control cells 
Results are reported as mean ± standard deviation (SD) from three different 
experiments in triplicate.  
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FGFR2b-mediated phagocytosis and autophagy are convergent intracellular 
membrane pathways regulated by PLCγ  signaling.  
 
It has been recently demonstrated that FGFR2b expression and signaling 
trigger both autophagy (Belleudi et al., 2014) and phagocytosis (Cardinali et al., 
2005; Belleudi et al., 2011) in human keratinocytes. To assess the existence of a 
possible coordination between FGF7-induced autophagy and phagocytosis and to 
ascertain whether these processes could involve converging autophagosomal and 
phagosomal compartments, we took advantage of the use of an in vitro model of 
bead uptake widely used to study the phagocytic capacity of epidermal 
keratinocytes (Wolff et al., 1972; Virador et al., 1992; Desjardins et al., 2003). The 
ability of the human keratinocyte HaCaT cell line, spontaneously immortalized 
from a primary culture of keratinocytes (Boukamp et al., 1988), to either engulf 
and to sort the engulfed beads to the degradation also via autophagy was 
analyzed in response to FGF7. To this aim HaCaT cells were transiently 
transfected with pEGFP-C2-LC3 construct and stimulated with FGF7 for 24 h. For 
the last 4 h of the treatment cells were also incubated with inert latex red 
fluorescent beads 0.5 mm in diameter. Concentrations of both FGF7 and bead, as 
well as the times of treatments, were selected based on our published results 
(Cardinali et al., 2005; Cardinali et al., 2008; Belleudi et al., 2011). Cells were fixed, 
permeabilized and nuclei were stained with DAPI. Quantitative fluorescence 
analysis performed as reported in Materials and Methods, showed that, as 
expected, the treatment with FGF7 increased bead uptake (Cardinali et al., 2005; 
Belleudi et al., 2011) (Figure 6A) as well as the amount of EGFP-LC3 positive dots 
per cell (Belleudi et al., 2014) (Figure 6A). In addition, only a part of internalized 
fluorescent beads (18%) appeared to colocalize with LC3 (Figure 6A). This not so 
tight colocalization and the presence of distal formation of autophagosomes (LC3-
positive dots which did not colocalize with beads) strongly indicated that LC3 
associates with canonical new-formed autophagic vesicles and not directly with 
the membrane of all the nascent phagosomes, as occurs during the LC3-associated 
phagocytosis (LAP). This is in agreement with previous findings demonstrating 
that inert beads fail to activate LAP in macrophages (Martinez et al., 2015). In 
order to unequivocally demonstrate that these LC3 positive dots containing beads 
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may correspond to autophagosomal structures, electron microscopy studies were 
performed in HaCaT cells stimulated with beads in presence of FGF7 as above. 
Ultrastructural examination revealed the presence of single (Figure 6B, asterisks, i, 
ii, iii) and clustered beads (Figure 6B, asterisks, iv) in either single-membrane 
(Figure 6B, arrows, ii) and double-membrane (Figure 6B, arrowheads, ii, iii, iv) 
vacuoles corresponding to phagosomes and autophagosomes, respectively. 
Several clustered beads are also visible in vacuoles ultrastructurally recognizable 
as lysosomes (data not shown), confirming that, independently from the chosen 
pathway, the final fate for the engulfed beads is the accumulation in the 
degradative compartment. These results clearly suggest that, in response to FGF7, 
part of the phagosomes containing the engulfed beads are isolated in new-forming 
autophagosomes, that possibly mediate their targeting to lysosomes.  
Since PLCγ activation/phosphorylation is required for FGFR2b-mediated 
phagocytosis (Belleudi et al., 2011), to investigate the role of this signaling in 
FGF7-induced autophagy we transiently transfected HaCaT cells with a FGFR2b 
signaling mutant in which the tyrosine 769, required for PLCγ  binding and 
activation (Ceridono et al., 2005; Cha et al., 2009) has been substituted by 
phenylalanine (Y769F) (Ceridono et al., 2005). The transfection with FGFR2b wild 
type (HaCaT FGFR2b WT), with a Y656F/Y657F FGFR2b kinase dead mutant 
(HaCaT FGFR2b kin-) (Belleudi et al., 2006) or with pCI-neo empty vector (HaCaT 
pCI-neo) was used as control. After transfection, cells were serum-starved and 
stimulated with FGF7 for 24 h and the amount of the widely accepted marker for 
autophagosomes (Kabeya et al., 2000; Wu et al., 2006), the 16-kDa membrane-
associated microtubule associated protein 1 light chain 3-II (LC3-II) was analyzed 
by western blot. To focus the attention on the possible impact of PLCγ signaling 
shut-down exclusively on the assembly step of the autophagosomes, their 
degradation was selectively blocked stimulating cells with FGF7 in the presence of 
bafilomycin A1, an inhibitor of the vacuolar type H+-ATPase (v-ATPase) able to 
block the fusion of autophagosomes with lysosomes (Juhász et al., 2012). We 
selected this drug for the interference of the autophagosome-to-lysosome fusion 
because, differently from other agents, including monensin or chloroquine, 
bafilomycin does not activate LC3 association with single intracellular membrane, 
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such as endosomes or lysosomes (Florey et al., 2015). The results surprisingly 
showed that, in a similar manner to what observed in cells overexpressing 
FGFR2b kin- (Figure 7A), in cells overexpressing FGFR2b Y769F the amount of 
LC3-II level was not affected by FGF7 stimulation (Figure 7A), suggesting that 
PLCγ signaling downstream FGFR2b is indispensable for FGF7-induced 
autophagosome assembly. In agreement with our previous evidences (Belleudi et 
al., 2014) the increase of LC3-II levels after serum deficiency was further increased 
in response to FGF7 in pCI-neo cells (Figure 7A) and appeared more pronounced 
in FGFR2b WT cells (Figure 7A). The impact of PLCγ signaling in the induction of 
autophagy was also investigated by fluorescence approaches. To quantify the 
autophagosome number in cells forced to overexpress the different forms of 
FGFR2b, HaCaT cells were alternatively co-transfected with pEGFP-C2-LC3 
construct and pCI-neo empty vector, FGFR2b WT, FGFR2b kin- or the FGFR2b 
Y769F. Cells were then treated with FGF7 as above, fixed, permeabilized and 
nuclei were stained with DAPI. Quantitative immunofluorescence analysis 
performed using anti-FGFR2b polyclonal antibody, to visualize transfected 
FGFR2b WT or mutants, showed that, similarly to FGFR2b kin-, FGFR2b Y769F 
overexpression induced a drastic reduction of the number of LC3-positive dots 
compared to that observed in HaCaT EGFP-LC3/pCI-neo and in HaCaT EGFP-
LC3/FGFR2b WT cells (Figure 7B) or in HaCaT EGFP-LC3/FGFR2b Y769F and in 
EGFP-LC3/FGFR2b kin- surrounding cells not showing detectable receptor mutant 
overexpression (Figure 7B, arrowheads). On the other hand, differently from the 
kinase dead mutant (Figure 7B), both FGFR2b WT and FGFR2b Y769F signals 
appeared concentrated in intracellular dots (Figure 7B) confirming that PLCγ 
signaling is not required for ligand-dependent receptor internalization (Ceridono 
et al., 2005). Overall our evidences strongly suggest that the specific signaling 
downstream PLCγ is indispensable for FGF7-induced autophagy and that its shut-
down results in a significant inhibition of the process. 
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FGFR2b-induced autophagy requires PLCγ-mediated phosphorylation/ 
activation of JNK.  
 
Autophagy can be controlled by several mTOR-dependent or mTOR-
independent signaling pathways (Yang et al., 2010; Russell et al., 2014). While it 
has been demonstrated that FGF2 negatively impacts on autophagy through the 
activation of AKT/mTOR signaling (Lin et al., 2011; Zhang et al., 2012), it has been 
recently demonstrated that FGF7 increases autophagy through a not yet identified 
PI3K/AKT/mTOR-independent pathway (Belleudi et al., 2014). Therefore, we 
focused our attention on the JNK1-mediated signaling pathway, which is mTOR-
independent (Russel et al., 2014) and it has been recently identified as mainly 
involved in FGFR4-mediated autophagy in osteoclasts (Cinque et al., 2015). In 
order to assess the possible impact of the JNK1 pathway in FGF7-mediated 
autophagy, and to establish if and how PLCγ is involved in the activation of the 
JNK1 pathway, we compared the levels of phosphorylation/activation of this 
kinase and of other important FGFR2b signaling substrates involved in the control 
of autophagy, such as ERK1/2, in HaCaT pCI-neo, HaCaT FGFR2b WT cells and 
HaCaT FGFR2b Y769F cells. AKT phosphorylation was checked to further confirm 
the independence of FGF7-mediated autophagy from the canonical 
PI3K/AKT/mTOR regulating pathway. Western blot analysis showed that upon 
FGF7 stimulation all the checked substrates appeared phosphorylated in HaCaT 
pCI-neo and HaCaT FGFR2b WT cultures, indicating that in these cells all the 
signaling pathways downstream FGFR2b are activated (Figure 8A). In contrast, in 
HaCaT FGFR2b Y769F cells ERK1/2 and AKT appeared normally phosphorylated, 
while JNK1 phosphorylation was significantly reduced (Figure 8A). These 
evidences indicated that PLCγ recruitment to FGFR2b and its consequent 
phosphorylation are required for an efficient activation of the JNK1-mediated 
signaling pathway.  JNK1 pathway is canonically activated by several MAP3 
kinases, which in turn activate MKK4 and MKK7 that induce JNK 
phosphorylation (Katz et al., 2007). However, it has been recently demonstrated 
that PKCδ is the upstream substrate mainly responsible for the activation of the 
JNK1 pathway, during hypoxia-mediated autophagy (Chen et al., 2008; Chen et 
al., 2009). PKCδ is a direct substrate of PLCγ (Steinberg, 2008) activated by FGFRs, 
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including FGFR2 (Kim et al., 2003). In order to establish the relevance of PKCδ 
activation in the triggering of FGF7-mediated autophagy, we compared its 
phosphorylation levels in cells alternatively overexpressing FGFR2b or FGFR2b 
Y769F or pCI-neo as control. Western blot analysis clearly demonstrated that, in 
agreement with the observed attenuation of JNK1 phosphorylation, a 
corresponding reduction of PKCδ phosphorylation was detectable in cells 
overexpressing FGFR2b Y769F (Figure 8B). These findings strongly suggest that in 
FGFR2b Y769F cells the observed block of FGF7-induced autophagy is due to the 
inhibition of PLCγ−mediated signaling, which is accompanied by PKCδ 
inactivation and possibly consequent JNK1 pathway shut-down.  
To ascertain the relevance of JNK1 repression for the block of FGF7-induced 
autophagy observed in cells expressing FGFR2b PLCγ signaling mutant, we 
estimated the impact of specific kinase inhibitors on LC3-II levels in either HaCaT 
pCI-neo and in HaCaT FGFR2b WT. For JNK1, we used the same JNK inhibitor 
(SP600125) used to interfere with FGF18/FGFR4-triggered autophagy (Cinque et 
al., 2015), while the impairment of ERK1/2 signaling was obtained using the 
inhibitor of the upstream substrates MEK1/2, which efficiently blocks this 
pathway during ligand-mediated activation of FGFRs (Nakanishi et al., 2015). The 
effect of the AKT inhibitor previously used by us (Belleudi et al., 2011; Belleudi et 
al., 2014) was checked again to further confirm that the canonical 
PI3K/AKT/mTOR pathway could not affect the FGF7-mediated autophagy. 
Western blot analysis performed using antibodies directed against the 
phosphorylated forms of each substrate confirmed that all the inhibitors were 
highly specific (Figure 9). Results obtained in both HaCaT FGFR2b WT and 
HaCaT pCI-neo cells showed that only the JNK1 inhibitor was able to interfere 
with increase of LC3-II induced by FGF7 (Figure 10C), while both AKT and 
MEK1/2 inhibitors were ineffective (Figure 10A and B). The impairment induced 
by JNK1 inhibitor on FGF7-induced LC3 increase was comparable to that observed 
in cells expressing the PLCγ-mediated signaling mutant FGFR2b Y769F (Figure 
7A), strongly suggesting that in FGFR2b Y769F-expressing cells the observed 
attenuation of JNK1 signaling is responsible for the repression of FGF7-triggered 
autophagy. Since we have postulated that PKCδ could be possibly the substrate 
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downstream PLCγ acting upstream JNK1, we also analyzed the effect of the direct 
inhibition of PKCδ on autophagy. We found that in cells stimulated with FGF7, 
the treatment with the PKCδ inhibitor resulted in reduction of 
phosphorylation/activation of PKCδ (Figure 9) and in a repressive effect on LC3-II 
levels (Figure 10D) that was comparable to that found upon JNK1 inhibition 
(Figure 10C) or PLCγ signaling shut-down in FGFR2b Y769F expressing cells 
(Figure 7A). Overall our results suggest that the PLCγ signaling pathway is the 
main responsible for the triggering of FGFR2b-induced autophagy. The use of 
specific inhibitors confirmed that the autophagic process controlled by FGFR2b is 
PI3K/AKT/mTOR independent and requires the activation of JNK1, which 
possibly occurs via PKCδ activation. 
 
 
FGFR2b enhances FGF7-mediated autophagy, phagocytosis and their 
convergence in light skin primary HKs.  
 
It has been previously demonstrated that FGFR2b-induced PLCγ signaling 
is required for FGF7-stimulated phagocytosis and consequent melanosome uptake 
in keratinocytes (Belleudi et al., 2011); here we demonstrated that the same 
signaling pathway is involved in FGFR2b-mediated autophagy in these cells and 
that FGF7-mediated phagocytosis and autophagy are converging pathways to 
possibly ensure melanosome degradation. In agreement with this possibility, in 
HKs from light skin, where FGFR2b-mediated uptake of the melanosomes is 
higher than in HKs from dark skin as a consequence of an higher expression of 
FGFR2b (Cardinali et al., 2008), the reduced number of intracellular melanosomes 
was the consequence of an accelerated ability to degrade them by autophagy 
(Murase et al., 2013). In a recent work we also speculated that in light skin HKs 
FGFR2b, in virtues of its ability to accelerate the autophagosome turnover, could 
be responsible for melanosome removal via autophagy (Belleudi et al., 2014). On 
the base of this hypothesis we wondered if FGFR2b could be involved not only in 
the regulation of both phagocytosis and autophagy, but also in the fine control of 
their balance. To ascertain it, we used again the in vitro model of bead uptake and 
we compared the ability of HKs from light and dark skin to either engulf and to 
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sort the engulfed beads to the degradation via autophagy in response to FGF7. To 
this aim, light and dark keratinocytes were transiently transfected with pEGFP-
C2-LC3 construct and treated with FGF7 and with inert latex red fluorescent beads 
as above. Quantitative fluorescence analysis performed as reported in Materials 
and Methods, confirmed that, as expected (Cardinali et al., 2008) and consistently 
with the increased expression of FGFR2b (Figure 11), the treatment with FGF7 
increased the bead uptake more in light skin keratinocytes than dark skin ones 
(Figure 12). In addition, in light skin HKs, FGF7 stimulation significantly 
increased the amount of EGFP-LC3 positive dots per cell more that in dark ones 
and only a part of beads (26%) colocalized with them (Figure 12). In the complex 
the results indicate that, in light skin HKs, but not in the dark ones, the uptake of 
beads and their confluence in nascent autophagosomes for sorting to degradation 
are both enhanced by FGF7 stimulation.  
 
 
Impairment of FGFR2b-induced autophagy in HPV16E5 expressing 
keratinocytes 
  
It has been demonstrated that FGFR2b expression can be down-regulated, 
both transcriptionally and post translationally, by the early protein E5 of the 
human papillomavirus type 16 (HPV16) (Belleudi et al., 2011; Purpura et al., 2013), 
which represents a major risk factor for cervical cancer development and 
progression (zur Hausen, 2002; Moody and Laimnins, 2010). The E5 protein is a 
small, weakly oncogenic protein, which cooperates with the two oncogenes of 
HPV16, E6 and E7, promoting epithelial transformation and cervical 
carcinogenesis (Moody and Laimins, 2010; Venuti et al., 2011; DiMaio and petti, 
2013). The oncogenic activity of the E5 protein is also related to its ability to 
interfere with the expression signaling and trafficking of different receptor 
tyrosine kinases (RTKs) (Belleudi et al, 2011; reviewed in DiMaio and Petti, 2013). 
Consistently with the widely described correlation between autophagy and 
oncogenic virus infection (Mack and Munger, 2012; Silva and Jung, 2013), recent 
evidences have proposed the existence of an interplay between autophagy and 
HPV16 infection. In fact, autophagy seems to be induced after HPV16 infection in 
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host epithelial cells while the inhibition of this process enhances the viral 
infectivity (Griffin et al., 2013). Interestingly, another study has demonstrated that 
the depletion of all the HPV16 early proteins leads to a strong increase of 
autophagy in infected cervical keratinocytes (Hanning et al., 2013), suggesting for 
the entire “early protein group” of HPV16 an inhibitor role on autophagy. 
Nevertheless, the single contribution of each of the early proteins and the 
molecular mechanisms involved remain to be clarified. Starting from the 
observation that E5 protein of HPV16 (16E5) down-regulates the expression of 
FGFR2b (Belleudi et al., 2011; Purpura et al., 2013), which is able to induce 
autophagy in human keratinocytes (Belleudi et al., 2014),	 we investigated the 
effects of 16E5 ectopic expression on FGF7-induced autophagy in human 
keratinocytes.  
 To this aim, HaCaT cells were transiently transfected with pCI-neo E5-HA 
expression vector (Ashrafi et al., 2005) (HaCaT E5) or with the empty vector alone 
(HaCaT pCI-neo). The expected high expression of 16E5 mRNA transcript levels 
in HaCaT E5 (Purpura et al., 2013) was first confirmed by real-time relative RT-
PCR and normalized with respect to the levels of the viral protein transcript in the 
HPV16-positive cervical epithelial cell line W12 (Stanley et al., 1989) at the passage 
6 (W12p6) (Figure 13A). Then, to investigate the possible effects of 16E5 expression 
on FGF7-induced autophagy, HaCaT pCI-neo and HaCaT E5 cells were serum-
starved in the presence or absence of FGF7 for 24 h. Both the growth factor 
concentration and the single time point of treatment have been previously selected 
as optimal experimental conditions for an efficient autophagic induction in HaCaT 
cells (Belleudi et al., 2014). The amount of LC3-II was monitored by western blot 
analysis. The results showed that, after FGF7 stimulation, the increase of the 16 
kDa band corresponding to LC3-II marker, evident in HaCaT pCI-neo cells (Figure 
13B), appeared significantly reduced in HaCaT E5 cells (Figure 13B), indicating 
that the FGF7-induced autophagosome formation was counteracted by the 
presence of 16E5. 
To more carefully investigate the effect of 16E5 expression on the 
autophagic flux, the levels of the well-known autophagy substrate SQSTM1/p62 
(sequestosome 1) were estimated by western blot analysis. The evident decrease of 
the 62 kDa band corresponding to SQSTM1, observed in HaCaT pCI-neo cells 
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upon FGF7 stimulation, appeared significantly recovered in HaCaT E5 cells 
(Figure 13C), indicating that the SQSTM1 degradation was prevented in 16E5-
expressing cells. Moreover, the accumulation of this autophagic substrate seems to 
indicate that the viral protein acts by inhibiting the formation of new 
autophagosomes, rather than by accelerating their turnover. 
The interference of 16E5 expression on the enhanced autophagy was also 
investigated by the widely accepted fluorescence approach. To directly quantify 
the autophagosome number in cells ectopically expressing 16E5 and to easily 
compare it with cells which did not express the viral protein, HaCaT cells were 
transiently cotransfected with pEGFP-C2-LC3 construct and pCI-neo E5-HA 
(HaCaT EGFP-LC3/E5) or pCI-neo empty vector (HaCaT EGFP-LC3) as a control. 
Cells were then treated with FGF7 as above, fixed, permeabilized and nuclei were 
stained with DAPI. Quantitative immunofluorescence analysis was performed 
using anti-HA monoclonal antibody to visualize the viral protein. Results clearly 
showed that, upon FGF7 treatment, a significant increase of the LC3-positive dots 
per cell, corresponding to the assembled autophagosomes, was evident in HaCaT 
EGFP-LC3 cells (Figure 13D, middle panels, arrows) or in HaCaT EGFP-LC3/E5 
cells not showing 16E5 expression (Figure 13D, lower panels, arrows), while this 
increase appeared significantly abolished in HaCaT EGFP-LC3/E5 cells highly 
expressing 16E5 (Figure 13D, lower panels, arrowhead). Interestingly, in these 
latter cells, the number of LC3 positive dots was even lower than that observed in 
serum-starved control cells (Figure 13D, upper panels). Since serum starvation is 
per se an autophagic stimulus, these results suggest that 16E5 might play a more 
general role, independent on FGF7, in autophagy impairment. 
 
To clarify whether the inhibition of FGF7-dependent autophagy induced by 
16E5 is directly related to its previously reported ability to down-regulate FGFR2b 
expression and signaling (Belleudi et al., 2011; Purpura et al., 2013), we first 
compared the effects of 16E5 expression to those induced by FGFR2b depletion. 
HaCaT cells were singly transfected with 16E5 cDNA or with a small interfering 
RNA for FGFR2/Bek (HaCaT FGFR2b siRNA) or an unrelated siRNA (HaCaT 
control siRNA) as control and then stimulated with FGF7 as above. In addition, in 
order to assess whether the possible effects induced by FGFR2b depletion can be 
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counteracted by its simultaneous forced expression, cells were also doubly 
transfected with FGFR2b siRNA and pCI-neo vector containing human FGFR2b 
WT (HaCaT FGFR2b WT cDNA/FGFR2b siRNA). Western blot analysis showed 
that both 16E5-transfected and FGFR2b-depleted cells not only displayed receptor 
down-regulation as expected (Purpura et al., 2013), but also a significant decrease 
of LC3-II levels as well as a block of SQSTM1 degradation in response to FGF7 
(Figure 14A). Moreover, the inhibitory effects on autophagy induced by FGFR2b 
depletion was reverted by the simultaneous overexpression of the receptor (Figure 
14A). Thus, 16E5 expression and FGFR2b silencing appeared to affect the 
autophagic process in a similar manner. To further demonstrate the receptor 
involvement on the 16E5 effect on autophagy, we performed FGFR2b forced 
overexpression in the presence of the viral protein: to this aim, cells were 
transiently cotransfected with 16E5 (HaCaT E5) and FGFR2b WT (HaCaT 
E5/FGFR2b WT) or the kinase negative mutant FGFR2bY656F/Y657F (HaCaT E5/ 
FGFR2b kin-). After transfection, cells were stimulated with FGF7 as above. 
Western blot analysis clearly showed that the 16E5-induced decrease of LC3-II 
levels as well as SQSTM1 accumulation was reverted by the expression of FGFR2b 
WT, but not by that of FGFR2b kin- (Figure 14B). Therefore, FGFR2b forced 
expression and receptor activation are sufficient to counteract the inhibitory effect 
of 16E5 on the autophagy upon growth factor treatment. These results 
demonstrate that, although the molecular mechanisms remain to be clarified, 16E5 
appears to impact the pro-autophagic FGFR2b pathway through the down-
regulation of the receptor. 
To deeper investigate the possibility that 16E5 might play a more general 
role in autophagy impairment, the possible effects of its ectopic expression were 
analyzed in cells subjected to serum starvation, an autophagic stimulus in which 
the contribution of FGFR2b signaling is completely excluded. HaCaT pCI-neo and 
HaCaT E5 cells were kept in complete medium or serum-starved for the two time 
points (24 h and 48 h) previously selected as optimal conditions for an efficient 
induction of autophagy in HaCaT cells (Belleudi et al., 2014). Western blot analysis 
performed as above showed that in HaCaT E5 cells the progressive increase of 
LC3-II marker was significantly affected (Figure 15A), while the SQSTM1 
degradation was totally abolished (Figure 15B). The 
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expression was also investigated by immunofluorescence as above. The results 
showed that the significant increase of the LC3-positive dots induced by 24 h of 
serum starvation, evident in HaCaT EGFP-LC3 (Figure 15C, arrow), was 
completely blocked in HaCaT EGFP-LC3/E5 (Figure 15C, arrowheads), 
unequivocally demonstrating that the presence of the viral protein prevents the 
increase of autophagosomes in response to serum deprivation. Thus, 
independently from the stimulus that triggers the process, 16E5 appears to 
generally interfere with autophagy. 
In order to confirm that 16E5 is able to impact the autophagy on-rate, rather 
than the autophagy off-rate, as already indicated above by SQSTM1 monitoring, 
immunofluorescence experiments were performed doubly transfecting HaCaT 
cells with 16E5 and a pDest-mCherry-EGFP-LC3 tandem construct (Pankiv et al., 
2007). In fact, mCherry-EGFP-LC3 is an autophagic flux sensor, since EGFP 
fluorescence is quenched in acidic environments, whereas mCherry is an acidic-
stable fluorescent tag: the nascent autophagosomes are both red and green 
(yellow) labeled, whereas the acidic autolysosomes appear red, as a consequence 
of the EGFP quenching. Quantitative immunofluorescence analysis performed 
upon either serum deprivation and FGF7 stimulation showed that 16E5 expression 
led to a significant decrease in the number of yellow dots per cells corresponding 
to newly assembled autophagosomes (Figure 16A), while the quantity of red dots 
corresponding to autophagosomes flowed in the lysosomes was not affected 
(Figure 16A). The inhibitory effect of 16E5 on autophagosome formation was 
further confirmed monitoring the LC3-II levels in presence or absence of the well 
known lysosomal protease inhibitor leupeptin (LEU, Figure 16B), which inhibits 
the vacuolar type H+-ATPase (v-ATPase) complex necessary for lysosomal 
acidification (Juha ́sz et al., 2012). Western blot analysis performed upon serum 
deprivation or FGF7 stimulation showed that 16E5 expression significantly 
decreases LC3-II levels also in the presence of the inhibitor of the autophagic flux 
(Figure 16B), confirming that, independently from the stimulus that triggers 
autophagy, 16E5 exerts an inhibitory role in the autophagosome assembly. 
In order to define whether the effect of 16E5 on autophagy could be dose-
dependent, we took advantage of the use of HaCaT cells stably transfected with 
the construct pMSG 16E5 (HaCaT pMSG E5) (Oelze et al., 1995), in which the 
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expression of the viral protein can be progressively induced, in a time-dependent 
manner, by treatment with dexamethasone (Dex). The HaCaT pMSG cells were 
used as negative control. Cells were left untreated (0 h) or treated with Dex for 12 
h or 24 h, and the increasing 16E5 mRNA transcript levels were quantitated by 
real-time relative RT-PCR. The mRNA amounts were normalized respect to the 
levels expressed in W12p6 cells. The results clearly indicated that in HaCaT pMSG 
E5 cells, which expressed very low levels of 16E5 mRNA also in absence of Dex 
treatment (Oelze et al., 2015; Muto et al., 2011; French et al., 2013), the increasing 
levels of 16E5 mRNA after Dex stimulation remain lower than those observed in 
the endogenous model of W12p6 cells (Figure 17A). To first analyse the impact of 
the progressive expression of 16E5 on basal autophagy, cells were kept in 
complete medium and treated with Dex as above. Western blot analysis showed 
that in HaCaT pMSG E5 cells the low expression of LC3-II protein was decreased 
already after 12 h of Dex treatment and no further decrease was observed after 24 
h (Figure 17B, left panel). Interestingly, no changes on LC3-II amounts were 
induced by Dex in control cells (Figure 17B, left panel), demonstrating that the 
inhibitory effect observed in HaCaT pMSG E5 cells can be specifically ascribed to 
16E5 expression. In addition, these results indicate that the observed inhibition of 
autophagy does not occur only when the viral protein is overexpressed. 
Then, our attention was shifted from the basal to induced-autophagy. 
Western blot analysis showed that the evident increase of LC3-II levels induced by 
both serum starvation (Figure 17B, middle panel) and FGF7 stimulation (Figure 
17B, right panel) appeared completely abolished upon Dex treatment in HaCaT 
pMSG E5 cells; again, no effects were found in control cells, confirming the 
exclusive role of 16E5. Interestingly, in absence of Dex treatment, the increase of 
LC3-II protein caused by FGF7 appeared significantly lower in HaCaT pMSG E5 
than in control cells (Figure 17B, right panel), implying that the low levels of 16E5 
expressed by these cells in Dex-untreated conditions (see Figure 17A) were 
sufficient to interfere with the enhancement of autophagy induced by FGF7 
(Figure 17B, right panel). The ability of 16E5 to inhibit autophagy was also 
analyzed in detail by transmission electron microscopy (TEM). The ultrastructural 
observations revealed that the double-membrane autophagic vacuoles (Figure 
17C, asterisks), varying in shapes and frequently tightly apposed to endoplasmic 
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reticulum cisternae, were numerous in HaCaT pMSG cells treated with FGF7 in 
the presence of Dex (Figure 17C, left and middle panels) and drastically reduced 
in HaCaT pMSG E5 subjected to the same treatment (Figure 17C, right panel). 
Thus, the ultrastructural analysis unequivocally demonstrated that the 16E5-
induced impairment of autophagy shown by biochemical or immunofluorescence 
approaches corresponds to a real reduction in the number of double-membrane 
vacuolar structures morphologically identifiable as autophagosomes. 
To verify whether the viral protein exerts the inhibitory effect on autophagy 
also in the presence of the HPV16 full-length genome, as it occurs in the context of 
cervical carcinogenesis, we used the well established in vitro model of cervical 
W12p6 cells, containing episomal HPV16. Western blot analysis clearly showed 
that no detectable changes in LC3-II marker levels could be found in these cells 
upon starvation or FGF7 treatment (Figure 18A). Fluorescence approaches were 
also performed using W12p6 cells transiently transfected with pEGFP-C2-LC3 
(W12p6 EGFP-LC3). HaCaT cells or primary cultures of normal human 
keratinocytes (HKs) transiently transfected with EGFP-LC3 (HaCaT EGFP-LC3 
and HKs EGFP-LC3) were used as controls. The results clearly demonstrated that, 
differently from control cells (Figure 18B), W12p6 EGFP-LC3 cells did not show 
any increase in the number of LC3-positive dots per cell after serum starvation 
and/or FGF7 stimulation (Figure 18B). 
In order to investigate whether the lack of responsiveness to the autophagic 
stimuli detected in the endogenous context of W12p6 cells may be due to 16E5 
expression, the effect of specific depletion of the viral protein was analyzed by 
siRNA transfection. We first confirmed the efficient depletion of the 16E5 protein 
in E5 siRNA-transfected cells performing experiments on HaCaT cells 
cotransfected with E5-HA cDNA and E5 siRNA in which the efficiency of 16E5 
silencing was verified through western blot analysis using anti-HA monoclonal 
antibody (Figure 19). Then, W12p6 cells were transfected with the specific 16E5 
siRNA or with an unrelated siRNA as control and the autophagic process was 
stimulated by serum starvation or FGF7 treatment as above. Western blot analysis 
clearly showed that both the autophagic stimuli significantly increased the LC3-II 
levels only in 16E5-depleted cells (Figure 18C). Consistent with the biochemical 
results, fluorescence approaches revealed that a significant increase of LC3-
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positive dots was evident in 16E5-depleted W12 cells upon serum deprivation and 
FGF7 stimulation (Figure 18D), while no increase was found in control siRNA-
transfected cells (Figure 18D). These results strongly indicated that in W12p6 cells, 
which are the most representative model of cervical cancerogenesis, the observed 
unresponsiveness to autophagic stimuli could be specifically ascribed to 16E5 
expression. 
 
 
16E5 interferes with the transcriptional regulation of autophagy through the 
impairment of p53 function  	
Since it has been demonstrated that 16E5 is able to affect the expression of 
several host genes (Kivi et al., 2008; Greco et al., 2011) and growing evidences 
indicate that autophagy is not only post-translationally regulated, but also 
transcriptionally controlled (Kusama et al., 2009; Rouschop et al., 2010; 
Kenzelmann Broz et al., 2013), here we investigated whether 16E5 might interfere 
with autophagy by affecting the autophagic gene expression. To this aim, the 
mRNA transcript levels of different crucial autophagic genes acting at different 
steps of the process (BECN1, ATG5 and LC3) were estimated by real-time relative 
RT-PCR in HaCaT E5 cells and normalized respect to the levels detected in HaCaT 
pCI-neo cells. In cells kept in complete medium, BECN1 and ATG5, but not LC3 or 
ATG7, appeared down-regulated by 16E5 expression (Figure 20A, upper panels). 
Moreover, when autophagy is stimulated by serum starvation or FGF7 treatment, 
a drastic significant decreased expression of all genes examined, except BECN1 in 
serum-deprived cells, was evident (Figure 20A, lower panels). Thus, 16E5 down- 
regulates autophagy gene expression when the process is induced as well as under 
basal conditions. Interestingly, in agreement with our previous biochemical 
observations (Belleudi et al., 2014), FGF7 stimulation slightly but significantly 
increased the expression of BECN1 and LC3, while that of ATG5 seemed 
unaffected (Figure 20A, lower panels) indicating that FGF7/FGFR2b signaling 
plays a role in the transcriptional control of autophagy. The p53 protein has been 
recently identified as a possible transcriptional inductor of the autophagic 
program (Kenzelmann Broz et al., 2013) and several autophagy genes are found to 
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be positively regulated by p53 also in HaCaT cells (Martynova et al., 2012), 
although these cells are known to express mutant p53 alleles (Martynova et al., 
2012). Therefore, in order to assess whether 16E5 might negatively affect the 
transcriptional program of autophagy also interfering with the expression of a set 
of p53-regulated autophagy core machinery genes (ULK1, ULK2, ATG4a, ATG7) 
(Kenzelmann Broz et al., 2013), we analyzed their transcript levels as above. Real-
time relative RT-PCR showed that all the p53-regulated genes, with the only 
exclusion of ULK2, were significantly down-regulated by 16E5 expression upon 
either serum starvation or FGF7 stimulation (Figure 20B). Thus, during induced-
autophagy, the viral protein is able to repress the expression of several autophagic 
genes, some of which are specific targets of p53. In addition, since no changes in 
the mRNA levels of the examined p53-target genes were observed upon FGF7 
treatment (Figure 20B), these results show that the FGFR2b transcriptional 
regulation of autophagy is p53-independent. In order to verify if 16E5 could 
interfere with the transcriptional regulation of autophagy inducing impairment of 
p53 function, the expression of two well established p53 downstream target genes, 
such as p21 and 14–3-3σ, was analyzed in HaCaT E5 and HaCaT pCI-neo cells 
upon serum starvation or FGF7 stimulation. RT-PCR analysis showed in 16E5-
expressing cells a significant decrease of p53 target gene expression (Figure 20B, 
lower panels), suggesting that 16E5 could be able to transcriptionally impair 
autophagy also interfering with p53 function. In contrast, consistent with the 
results described above, the stimulation with FGF7 was able to induce no 
significant changes of p21 or 14–3-3σ expression (Figure 20B, lower panels), 
further confirming that the induction of autophagy by FGF7 does not involve the 
p53 regulation. In order to verify if the ability of 16E5 to transcriptionally regulate 
autophagy is a general phenomenon, we examined the expression of the 
autophagic genes in primary human keratinocytes transiently transfected with 
16E5 (HKs E5) or with the pCI-neo empty vector (HKs pCI-neo) as control. The 
results showed that, also in primary cultures, the expression of 16E5 appeared to 
down-regulate most of the p53-independent (Figure 21A) and p53-regulated 
(Figure 21B) autophagy genes, as well as that of the main p53-target gene p21 
(Figure 8b). Consistently with the results obtained in HaCaT cells, also in HKs 
pCI-neo the stimulation with FGF7 significantly increased the expression of 
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BECN1, ATG5 and LC3, while p53-target genes appeared unaffected (Figure 21A 
and B), confirming that FGF7 appears to exert a transcriptional control only on the 
p53-independent autophagy genes. To assess whether the repression of the 
autophagic gene transcription induced by 16E5 could be observed in the presence 
of HPV16 full-length genome and to analyze whether this effect could be directly 
due to the E5 viral protein expression, all the previously examined genes were re-
analyzed in W12p6 cells transfected with a specific E5 siRNA or with un unrelated 
siRNA. The mRNA levels of the different genes in HKs were used as normalizers. 
Real-time relative RT-PCR showed that the very low levels of most of the genes in 
W12p6 control siRNA cells (Figure 21C and D) were recovered upon 16E5 
depletion (Figure 21C and D). These results strongly suggested that the decreased 
expression of both p53-regulated and p53-independent autophagic genes observed 
in W12 cells compared to HKs can be directly ascribed to 16E5 expression. 
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In the first part of this work I investigate the crosstalk between autophagy 
and phagocytosis in human keratinocytes and the possible involvement of 
FGFR2b-induced PLCγ signaling in the induction of the FGF7-mediated 
autophagic process. The interplay between autophagy and phagocytosis is widely 
accepted to occur in the context of macrophages (Gutierrez et al., 2004; Sanjuan et 
al., 2007; Xu et al., 2007; Lima et al., 2011; Bonilla et al., 2013); however, a similar 
crosstalk has not been already described in other cell types. In this work, not only 
we confirmed our previous results showing that FGF7 stimulation is able to 
trigger either phagocytosis (Belleudi et al., 2011) and autophagy (Belleudi et al., 
2014) in both HaCaT keratinocyte cell line and in primary HKs, but interestingly 
we found that the activation and signaling of FGFR2b are able to drive 
phagosomes and autophagosomes to converge. This phenomenon might be 
explained as an additional strategy of this type of cells to more efficiently redirect 
the engulfed material toward a lysosomal degradative fate. 
It has been reported that, in addition to the conventional autophagy, several 
non-canonical autophagic mechanisms can be activated and, in particular, a direct 
recruitment of Beclin 1 and LC3 to the phagosomal membranes has been described 
as LAP (LC3-associated phagocytosis) in murine macrophages during 
phagocytosis (Sanjuan et al., 2007). However, our findings strongly indicate that, 
in our cell model, the autophagic process involves a canonical pathway to isolate 
the newly formed phagosomes. In fact, our fluorescence results, showing a not 
complete colocalization between the internalized beads and the LC3-positive dots 
upon FGF7 stimulation, appears to exclude the involvement of a non-canonical 
autophagy, such as LAP. In addition, our ultrastructural analysis showed that part 
of the engulfed beads were included in double membrane organelles 
morphologically corresponding to canonical autophagosomes, suggesting that 
some of the autophagosomal structures might close around the phagosomes 
containing the beads. Although this canonical intracellular membrane pathway 
may represent the main mechanism involved in such convergence of the two 
processes, several single membrane organelles containing beads were also visible: 
therefore, we may speculate that, as previously described in macrophages during 
bacterial clearance (Levine et al., 2011), also in keratinocytes other mechanisms, 
including the fusion between the phagosomal membrane and the outer membrane 
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of autophagosomes, can not be excluded.  
The ability of FGFR2b to regulate the phagocytic process appears to be 
functionally linked to the control of the melanosome uptake by recipient 
keratinocytes for skin pigmentation (Cardinali et al., 2005; Belleudi et al., 2011). In 
fact, this ability is more efficient in HKs from light skin, that are known to express 
more FGFR2b compared to those from dark skin (Cardinali et al., 2008). In the 
other hands, a recent study highlighted the crucial role of the autophagic process 
in melanosome degradation in the context of human keratinocytes (Murase et al., 
2013). Our present results, indicating a key role of FGFR2b not only in the 
induction of both autophagy and phagocytosis, but also in the regulation of their 
convergence, encouraged us to envisage a new scenario in which FGFR2b would 
differently control autophagy, and possibly melanosome turnover, in light and 
dark skin. This hypothesis appears to be confirmed by our fluorescence results 
showing that autophagy and phagocytosis may converge only in HKs from light 
skin. Taken together our results indicate that, particularly in light skin, FGFR2b 
signaling could be crucial in determining melanosome intracellular amount and 
consequently skin pigmentation through a fine modulation of the interplay 
between phagocytosis and autophagy. Our speculations are consistent with those 
of Li and coworkers (Li et al., 2016), which hypothesized that the UVB-induced 
persistence of melanosomes, especially in HKs from light skin, can be due to the 
inhibition of autophagy consequent to UVB-mediated internalization and 
degradation of FGFR2b (Marchese et al., 2003; Belleudi et al., 2006). These authors 
also proposed that the modulation of FGF7-induced autophagy might be a useful 
strategy for treating skin pigmentation disorders (Li et al., 2016).  
 While in our previous work (Belleudi et al., 2011) it has been demonstrated 
that, in human keratinocytes, the FGFR2b-induced phagocytosis occurs via PLCγ 
signaling, suggesting that diacylglycerol formation and consequent cortical actin 
reorganization could be required, the molecular pathways responsible for FGF7-
induced autophagy remain to be clarified. It is well-known that the autophagic 
process can be regulated by either mTOR-dependent and mTOR-independent 
molecular mechanisms (Yang et al., 2010; Russell et al., 2014) and it has been 
previously demonstrated that FGF7-mediated autophagy is a PI3K/AKT/mTOR-
independent process (Belleudi et al., 2014). Therefore, in this work we further 
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progress on the identification of the molecular mechanisms underlying FGF7-
mediated autophagy, identifying PLCγ as a crucial player acting downstream 
FGFR2b. Using biochemical and immunofluorescence approaches we assessed the 
key role of the tyrosine 769 residue in FGFR2b, responsible for the 
activation/recruitment of PLCγ, not only in the receptor-mediated phagocytosis as 
previously shown (Belleudi et al., 2011), but also in the induction of autophagy. In 
fact, the point mutation of this receptor site (Y769F), which generates a PLCγ 
signaling dead mutant (FGFR2b Y769F), resulted in the impairment of the 
autophagosome formation following FGF7 stimulation. Thus, PLCγ signaling 
appears to be the main pathway involved in the regulation of both FGFR2b-
mediated phagocytosis and autophagy (Figure 22). 
Then, in order to identify the molecular machinery acting downstream PLCγ, 
we focused our attention on JNK1, a RTK substrate able to activate an mTOR-
independent autophagic pathway (Russell et al., 2014) and recently identified as 
the main player involved in FGFR4-mediated autophagy (Cinque et al., 2015). We 
found that, upon FGF7 stimulation, the phosphorylation/activation of JNK1 is 
strongly attenuated in cells overexpressing the FGFR2b Y769F mutant. Moreover, 
only the inhibition of JNK1, but not that of other FGFR2b substrates, such as 
MEK1/2 or AKT, was able to affect FGF7-mediated autophagy. These findings 
demonstrated that, consistently with what has been reported for FGFR4 in 
osteoclasts (Cinque et al., 2015), FGFR2b-mediated autophagy in keratinocytes is 
induced via the activation of JNK1 signaling. Taking advantage of the use of a 
specific inhibitor, we finally identified the PLCγ substrate PKCδ (Steinberg, 
Physiol Rev, 2008) as the molecular player directly involved in JNK1 activation 
and consequently in FGF7-induced autophagy. These results are consistent with 
previous findings indicating PKCδ as crucial activator of JNK1 during autophagy 
induced by hypoxia (Chen et al., 2008; Chen et al., 2009). 
Overall the data collected in the first part of this work strongly suggest that 
PLCγ is the FGFR2b substrate, which acts as an upstream regulator of both 
phagocytosis and autophagy in HKs. While the PLCγ-mediated  formation of 
diacylglycerol and consequent cortical actin reorganization might be responsible 
for the triggering of phagocytosis, PKCδ/JNK1 signaling would be the main 
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PLCγ downstream pathway required for the induction of FGF7-mediated 
autophagy (Figure 22).  
 
In the second part of this work, I focused my attention on the possible 
impairment of the autophagic response in keratinocytes expressing the 
oncoprotein 16E5.  
The interference of the host cell autophagic response is a general strategy 
used by viruses during the early steps of infection in order to ensure their 
intracellular survival and subsequent replication (Silva et al., 2013). In the case of 
human papillomavirus 16 (HPV16), a role in inhibiting the host cell autophagy has 
been proposed for the entire “early protein group” (Hanning et al., 2013), but 
neither the single contribution of the viral oncogenic proteins, nor the molecular 
mechanisms involved in such inhibition, have been investigated. Starting from our 
recent results dealing with the ability of FGF7/FGFR2b signaling in promoting 
autophagy (Belleudi et al., 2014) and with the capacity of HPV16 E5 to down-
regulate the receptor expression for perturbation of epithelial homeostasis and 
differentiation (Belleudi et al., 2011; Purpura et al., 2013), we speculated that 16E5 
might be the HPV16 early product major candidate for the role of interference 
with the autophagic process, possibly occurring through FGFR2b down-
modulation. Consistent with this hypothesis we demonstrated, using biochemical 
and immunofluorence approaches, that the ectopic expression of 16E5 efficiently 
counteracts FGF7-mediated autophagy. In fact, the inhibitory effects induced by 
the viral protein were comparable to those observed under receptor depletion and 
the forced receptor overexpression and the triggering of its signaling was able to 
contrast the repressive function of 16E5 on the autophagic process. These results 
suggest that 16E5 and FGFR2b would exert opposite and interplaying roles not 
only on epithelial differentiation, as recently proposed (Purpura et al., 2013), but 
also on the control of autophagy 
Interestingly, taking advantage of the use of serum starvation as autophagic 
stimulus in which the contribution of FGFR2b signaling was excluded, we 
provided the first evidence that 16E5 affects autophagy also through 
transcriptional regulation. In fact, our molecular analysis showed that 16E5 is able 
to repress most of the autophagy core machinery genes, some of which are direct 
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targets of p53, one of the main transcriptional inductor of the autophagic program 
(Kenzelmann Broz et al., 2013). However, differently from the 16E6 oncoprotein, 
whose crucial role as p53 down-regulator has been proposed (Scheffner et al., 
1990), only a modest ability to repress p53 expression has been ascribed to 16E5 
(Greco et al., 2011). Therefore, it is possible that, in the case of 16E5 expression, p53 
would be mainly functionally-regulated, rather than transcriptionally-regulated. 
To investigate such possibility we decided to analyze also the expression of the 
general p53-target genes p21 and 14–3-3σ, in order to monitor p53 function in our 
cell model (Martynova et al., 2012). In agreement with the hypothesis of a 
functional regulation of p53, we found that, when 16E5 is expressed and 
autophagy is induced by serum starvation or FGF7 stimulation a significant 
decrease in p53-target gene transcription was observed, indicating functional 
repression of p53. These results provide new elements to assume that the negative 
impact of 16E5 on autophagy might be also due to the ability of the viral protein to 
induce a functional inhibition of p53 activity, which in turn results in down-
regulation of autophagy genes. Moreover, the observed repressing effect on 
autophagy genes, which are not directly regulated by p53, suggests that 16E5 may 
in parallel interfere with other autophagy transcriptional regulators still unknown. 
It has been reported that autophagy is linked to epithelial cell differentiation 
(Haruna et al., 2008; Aymard et al., 2011; Chatterjea et al., 2011; Moriyama et al., 
2014 ; Belleudi et al., 2014, Chikh et al., 2014; Akinduro et al., 2016) and it has been 
recently proposed the existence of a direct interplay between the two processes in 
human keratinocytes demonstrating that the induction of autophagy in response 
to FGFR2b activation is necessary for the triggering of early differentiation 
(Belleudi et al., 2014). Accordingly with the knowledge that 16E5 acts during HPV 
infection perturbing keratinocyte differentiation (Fehrmann et al., 2003; Barbaresi 
et al., 2010) and that this occurs through FGFR2b down-modulation (Purpura et 
al., 2013), our present study shows that a finely controlled impairment of the 
autophagic process, also through FGFR2b down-regulation, could be one of the 
molecular mechanisms used by 16E5 to inhibit and delay epithelial cell 
differentiation for maintenance of an undifferentiated status indispensable for 
virus replication. 
	 52	
On the other hand, a close interplay between p53 activity and epidermal cell 
differentiation has been also proposed: in fact, in suprabasal differentiating 
keratinocytes, p53 is activated by the dramatic decrease of its functional repressor 
ΔNp63α (Westfall et al., 2003) and several keratinocyte differentiation-specific 
markers, including Notch1, Hsp70 and keratin 14, are finely regulated by the 
∆Np63α/p53 inverse functional cooperation (Agoff et al., 1993; Wu et al., 2005; 
Nguyen et al., 2006; Yugawa et al., 2007; Cai et al., 2012). Moreover, it has been 
observed that p53 activity promotes differentiation in HaCaT cells (Paramio et al., 
2000). Based on these evidences, our results may indicate that 16E5 is able to 
utilize parallel and not interconnected mechanisms, involving both FGFR2b 
down-regulation and functional repression of p53, for the impairment of both  
autophagy and differentiation. Since we demonstrated here that also the 
autophagy induced by FGF7 signaling appears to be transcriptionally controlled, 
although in a p53-independent manner, the data obtained in the second part of 
this work allow us to conclude that a transcriptional crosstalk among 16E5 and 
FGFR2b is the crucial molecular driver of epithelial deregulation during early 
steps of HPV infection and transformation. 
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mammalian cells and recognized the contribution of the 
lysosome to it (for a review, see REF. 11). By the 1970s, 
the improvements in transmission electron micro-
scopy and the development of cytochemical techniques 
enabled the concept of autophagy to be firmly estab-
lished. In parallel, starting in the 1960s, the origin of 
the autophagosome membrane was being investigated 
and debated. Interestingly, the ER was the first source 
identified12. Subsequently, a discrete membrane called 
a phagophore, with unique morphological properties, 
was identified as the potential initiating membrane of 
the autophagosome13. This membrane appeared unex-
pectedly in electron microscopy images as a double-
membrane cisterna, often as a curved, cup-shaped 
structure with a translucent lumen that stained heavily 
with osmium, thus giving it a darker appearance than 
other cellular membranes14. The osmophilic properties 
of the phagophore suggested that its lipid and protein 
composition is unique and distinct from other cellular 
membranes, and data obtained using freeze-fracture 
techniques have shown that it contains low levels of pro-
tein15. Although the initial electron microscopy studies 
suggested the phagophore, now also called the isola-
tion membrane, was derived from the ER or the GERL 
(Golgi–ER–lysosome), some evidence implied that it 
was assembled de novo16. The current consensus is that 
it arises from a subdomain of the ER (see below).
Biochemical approaches developed over the subse-
quent decades provided data that are the foundation for 
our current understanding of the molecular control of 
autophagy. The discovery of the pathway in yeast from 
electron microscopy analysis17 and the identification of 
the first yeast ATG (autophagy-related) genes18,19 trans-
formed the autophagy field. The molecular analyses of 
autophagy began in earnest in yeast and soon followed 
in mammalian cells. The first link between autophagy 
Figure 1 | Overview of the autophagic pathway and organelles that might contribute to autophagosome 
biogenesis. Whereas organelles in the biosynthetic and secretory pathways are always present in the cell, the 
autophagosome forms quickly and disappears, and its formation can be increased by signals that activate autophagy. 
Thus, the origin and source of the autophagosomal membrane is a major question in the field. Various organelles, 
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plasma membrane and recycling endosomes have been implicated in autophagosome formation (that is, in the nucleation 
of the isolation membrane (originally termed the phagophore)) and in the subsequent growth of the membrane. A fully 
formed autophagosome fuses with a lysosome to create an autolysosome, in which the material sequestered by the 
autophagosome is degraded and released into the cytoplasm for use in cellular processes, including protein biosynthesis 
and energy production. Autophagy is a cell survival pathway that is required to keep cells healthy by degrading damaged 
organelles and eliminating invading pathogens, but it has also been shown to be dysregulated in a number of human 
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Figure 1. Overview of the autophagic pathway and organelles that might 
contribute to autophagosome. Macroautophagy is mediated by a double-
membrane organelle called autophagosome, by which a portion of the cytoplasm 
is enclosed. The outer membrane of the autophagosome then fuses with the 
lysosome, which allows lysosomal enzymes to degrade the sequestered 
cytoplasmic materials in autolysosomes and release the degradation products into 
the cytoplasm for use in cellular processes, including protein biosynthesis and 
energy production. Whereas organelles in the biosynthetic and secretory 
pathways are always present in the cell, the autophagosome forms quickly and 
disappears, and its formation can be increased by signals that activate autophagy. 
Thus, the origin and source of the autophagosomal membrane is a major question 
in the field. Various organelles, including the endoplasmic reticulum (ER), 
mitochondria, mitochondria-associated membranes (MAMs), the Golgi, the 
plasma membrane and recycling endosomes have been implicated in 
autophagosome formation (that is, in the nucleation of the isolation membrane) 
and in the subsequent growth of the membrane. Autophagy is a cell survival 
pathway that is required to keep cells healthy by degrading damaged organelles 
and eliminating invading pathogens, but it has also been shown to be 
dysregulated in a number of human disease, (for example, Crohn’s disease, cancer 
and neurodegeneration), which makes it a potential target for future therapeutic 
intervention. MVB, multivesicular body. 
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However, while autophagic targeting of conventional 
cytoplasmic substrates needs formation of a membranous 
compartment that isolates the doomed item, autophagy against 
the contents of a vesicular structure could conceivably spare 
cargo isolation and rely only on LC3 labeling of an already 
existing vesicle. In fact, some recently described examples support 
this novel idea (Fig. 2B). In the following we review the new 
developments on this topic.
Phagosomes containing stimulated TLR2 (toll-like receptor 
2) become rapidly decorated with BECN1 to promote LC3 
labeling of this nonautophagic single-membrane compartment, 
a process that promotes more efficient acquisition of lysosomal 
features.33 This phenomenon has been called LC3-associated 
phagocytosis (LAP) and it has since been observed in different 
settings, including engulfment of dead cells,79 phagocytosis of 
Burkholderia pseudomallei,80 stimulation of phagosomal Fcγ-
receptors,81 efficient formation of phagosomal IRF7 (interferon 
regulatory factor 7)-signaling compartments in response to TLR9 
stimulation by DNA immune complexes,82 circadian degradation 
of phagocytosed photoreceptors by retinal pigment epithelial 
Figure  2. Scheme of the different modalities of autophagy involving membrane compartments and their functional consequences (bottom). 
(A) Regular, single-membrane vesicles are targeted by conventional autophagy to produce multimembrane vacuoles that fuse with lysosomes for 
degradation of their contents. (B) Regular, single-membrane vesicles become directly labeled with LC3-II and eventually fuse with lysosomes for deg-
radation. (C) Regular, single-membrane vesicles are targeted by conventional autophagy producing multimembrane vacuoles with nondegradative 
functions. (D) Regular, single-membrane vesicles or other membranous structures become directly labeled with LC3-II for a variety of nondegradative 
functions. (V, vesicle; MMs, multiple membranes; SM, single membrane; L, lysosome).
(modified from Pimentel-Muiños and  Boada-Romero, 2014)
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Figure 2. Scheme of the different modalities of autophagy involving membrane 
compartments. (A) Regular, single-membrane vesicles are targeted by 
conventional autophagy to produce multimembrane vacuoles that fuse with 
lysosomes for degradation of their contents. (B) Regular, single-membrane vesicles 
become directly labeled with LC3-II and eventually fuse with lysosomes for 
degradation. (C) Regular, single-membrane vesicles are targeted by conventional 
autophagy producing multimembrane vacuoles with nondegradative functions. 
(D) Regular, single-membrane vesicles or other membranous structures become 
directly labeled with LC3-II for a variety of nondegradative functions. (V, vesicle; 
MMs, multiple membranes; SM, single membrane; L, lysosome).  
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signal peptide found within the extracellular ligand bind-
ing-domain is cleaved off upon insertion into the endo-
plasmic reticulum, and FGFR5 is occasionally shed from
the plasma membrane and is found in a secreted, soluble
form [1]. FGFR5 binds to certain FGFs, as do the con-
ventional FGFRs, but it does not bind to FGF1, which is
also recognized by all of the other FGFRs [1].
Alternative splicing of FGFRs
Despite the general characteristics shared among the family
members of FGFRs, an array of isoforms exist within each
family member (Fig. 2). Structural diversity observed
across the isoforms of FGFRs, is largely attributed to the
alternative splicing of endogenous mRNA sequence. These
isoforms include the secreted form of FGFRs that lack the
hydrophobic membrane-spanning region and the entire
cytoplasmic catalytic domain [7, 8], FGFRs with an
extracellular domain composed of either two or three Ig-
like domains [7, 9–11], and FGFRs devoid of the acid box
[12].
One of the most important mechanisms that determine
the ligand-binding specificity of FGFRs is by alternate
exon usage of the IgIII (D3) domain to produce three
possible IgIII domains isoforms, designated IgIIIa, IgIIIb
and IgIIIc. IgIIIa is encoded entirely by exon 7 alone while
IgIIIb and IgIIIc are derived from alternative splicing of
exon 7/8 and exon 7/9, respectively (Fig. 2) [13–16]. The
IgIIIb and IgIIIc splice variants are commonly observed in
FGFR1, FGFR2 and FGFR3 gene [13, 17]. The FGFR4
gene is unique as only IgIIIc variants are present [18].
Ig-like Domain I (D1)
Ig-like Domain II (D2)
Ig-like Domain III (D3)
Signal Peptide
Acid Box
Transmembrane Domain
Tyrosine Kinase I
Tyrosine Kinase II
Carboxyl Terminal
Fig. 1 The basic structure of a FGFR. The FGFRs are phylogenet-
ically closely related to the VEGFRs and PDGFRs, consist of three
extracellular immunoglobulin (Ig) domains (D1-D3), a single trans-
membrane helix, an intracellular split tyrosine kinase domain (TK1
and TK2) and an acidic box. D2 and D3 form the ligand-binding
pocket and have distinct domains that bind both FGFs and heparan
sulfate proteoglycans (HSPGs). Acidic box is required for binding of
bivalent cations for optimal interaction between FGFRs and HSPGs
Fig. 2 FGFR splice variants. The FGFRs isoforms are generated
mainly by alternative splicing of the Ig III domain (D3). The D3 could
be encoded by an invariant exon 7 (red) to produce FGFR-IIIa isofom
or spliced to either exon 8 (green) or 9 (yellow) to generate the FGFR-
IIIb or FGFR-IIIc isoforms, respectively. Epithelial tissues predom-
inantly express the IIIb isoform and mesenchymal tissues express IIIc.
FGFR4 is expressed as a single isoform that is paralogous to FGFR-
IIIc. Hatched box represents a truncated carboxyl terminal. Clear box
indicates a deletion of an exon
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Figure 3. The basic structure of FGFR and splice variants. The FGFRs are 
phylogenetically closely related to the VEGFRs and PDGFRs, consist of three 
extracellular immunoglobulin (Ig) domains (D1-D3), a single transmembrane 
helix, an intracellular split tyrosine kinase domain (TK1 and TK2) and an acidic 
box. D2 and D3 form the ligand-binding pocket and have distinct domains that 
bind both FGFs and heparan sulfate proteoglycans (HSPGs). Acidic box is 
required for binding of bivalent cations for optimal interaction between FGFRs 
and HSPGs. The FGFRs isoforms are generated mainly by alternative splicing of 
the Ig III domain (D3). The D3 could be encoded by an invariant exon 7 (red) to 
produce FGFR-IIIa isofom or spliced to either exon 8 (green) or 9 (yellow) to 
generate the FGFR-IIIb or FGFR-IIIc isoforms, respectively. Epithelial tissues 
predominantly express the IIIb isoform and mesenchymal tissues express IIIc. 
FGFR4 is expressed as a single isoform that is paralogous to FGFR-IIIc. Hatched 
box represents a truncated carboxyl terminal. Clear box indicates a deletion of an 
exon.  
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paracrine secretion of FGF7 by fibroblasts may 
also contribute to cellular proliferation in vivo63. 
Interestingly, in some gastric cancer cell lines amplifica-
tion of FGFR2 is accompanied by deletion of the most 
C-terminal coding exon64. This results in the expres-
sion of a C-terminally truncated receptor, which can 
also be generated by aberrant splicing in cell lines that 
lack the C-terminal deletion. This C-terminal FGFR2 
truncation interferes with receptor internalization65, 
therefore preventing a potential mechanism of signalling 
attenuation and contributing to constitutive activation 
of the receptor.
Amplification of the chromosomal region 8p11–12, the 
genomic location of FGFR1, is one of the most common 
focal amplifications in breast cancer66–68, and occurs in 
approximately 10% of breast cancers, predominantly 
in oestrogen receptor (ER)-positive cancers66. FGFR1 
amplifications have also been reported in oral squamous 
carcinoma69 and are found at a low incidence in ovarian 
cancer70, bladder cancer71 and rhabodomyosarcoma72 
(TABLE 1). In contrast to FGFR2 amplifications, overexpres-
sion of wild-type FGFR1 occurs in cancer; it is unclear 
whether the higher levels of FGFR1 lead to tumours that 
aberrantly respond to paracrine FGF ligands, such as 
FGF2, or whether at higher levels of FGFR1 expression 
ligand-independent signalling occurs. It is also important 
to note that the 8p11–12 region is gene dense and it is not 
universally accepted that FGFR1 is the causative oncogene 
in this amplified region in breast cancer73,74. FGFR1 might 
also be important in breast cancers that lack FGFR1 ampli-
fications, and one study suggested that an FGFR inhibi-
tor blocked the proliferation of non-amplified cancer cell 
lines by downregulating D-type cyclins75.
Chromosomal translocations in haematological malig-
nancies. Some of the strongest evidence linking FGF 
signalling to oncogenesis has come from the study of 
haematological malignancies, in which translocations 
involving the FGFRs have been identified. Several 
FGFR intragenic translocations have been identified, 
which typically result in a fusion protein comprising the 
N terminus of a transcription factor fused to an FGFR 
kinase domain. This leads to constitutive FGFR dimeri-
zation and activation76–78 (TABLE 1). A different translo-
cation is found in multiple myeloma: 15% of multiple 
myelomas harbour a t(4;14) translocation that links 
FGFR3 at 4p16.3 to the immunoglobulin heavy chain 
IGH locus at 14q32 (REFS 79,80). These translocations 
are intergenic, with the breakpoints occurring ~70 kb 
upstream of FGFR3, and bring FGFR3 under the con-
trol of the highly active IGH promoter. It is important to 
note that the translocations involving FGFR3 in multi-
ple myeloma also involve the adjacent multiple myeloma 
SET domain-containing (MMSET) gene, and the relative 
contributions of FGFR3 and MMSET to oncogenesis are 
subject to ongoing debate81. However, the importance 
of FGFR3 overexpression and mutation in haemato-
logical malignancy has been modelled using transgenic 
mice82 (BOX 3), and t(4;14) myeloma cell lines are highly 
sensitive to FGFR3 targeting83,84.
FGFR3 translocation in multiple myeloma is asso-
ciated with a poor prognosis and is rarely found in 
monoclonal gammopathy of uncertain significance, a precur-
sor condition of multiple myeloma, which suggests that 
FGFR3 translocations promote a rapid conversion to full 
multiple myeloma85. The ultimate effect of the translo-
cation is to overexpress FGFR3 out of context, which 
might result in aberrant ligand-dependent signalling86 
(with hypersensitivity to ligands by swamping negative 
feedback and receptor internalization and degradation 
pathways) or ligand-independent signalling. In a small 
proportion of t(4;14) multiple myeloma, FGFR3 is also 
mutated (~5% translocated cases)87, presumably further 
Figure 1 | FGFR structure and control of ligand specificity. a | The basic structure of 
the fibroblast growth factor (FGF) –FGF receptor (FGFR) complex compris s t o receptor 
molecules, two FGFs and one heparan sulphate proteoglycan (HSPG) chain. The FGF 
signalling pathway comprises 4 highly conserved transmembrane receptors and 18 FGF 
ligands (BOX 1). FGFs bind with low affinity to cell surface HSPGs (purple) and with high 
affinity to specific FGFRs. The FGFRs, which are phylogenetically closely related to the 
vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor 
receptors (PDGFRs), consist of three extracellular immunoglobulin (Ig) domains, a single 
transmembrane helix and an intracellular split tyrosine kinase (TK) domain. The second 
and third Ig domains form the ligand-binding pocket and have distinct domains that bind 
both FGFs and HSPGs. b | Ligand-binding specificity is generated by alternative splicing of 
the Ig III domain. The first half of Ig III is encoded by an invariant exon (IIIa), which is spliced 
to either exon IIIb or IIIc, both of which splice to the exon that encodes the 
transmembrane (TM) region. Epithelial tissues predominantly express the IIIb isoform and 
mesenchymal tissues express IIIc. FGFR4 is expressed as a single isoform that is paralogous 
to FGFR-IIIc. c | Examples of the extent to which ligand specificity can differ between 
FGFR-IIIb and FGFR-IIIc isoforms, illustrated with the differing ligand specificty of FGFR2 
isoforms. The FGFR2-IIIb ligands are shown in blue and the FGFR2-IIIc ligands are shown in 
brown. For example, FGF7 and FGF10 bind specifically to FGFR2-IIIb and have essentially 
no binding to FGFR2-IIIc7. The mechanisms controlling splice isoform choice are 
becoming clearer and defined control elements have been identified in the introns 
surrounding alternatively spliced exons177–179.
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Figure 4.  FGFR2IIIb and FGFR2IIIb isoforms structure. Examples of the extent to 
which ligand specificity can differ between FGFRIIIb and FGFRIIIc isoforms, 
illustrated with the differing ligand specificty of FGFR2 isoforms. The FGFR2IIIb 
ligands are shown in blue and the FGFR2-IIIc ligands are shown in brown. For 
example, FGF7 and FGF10 bind specifically to FGFR2-IIIb and have essentially no 
binding to FGFR2IIIc. 																
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5
FGFR5 isoforms lacking the sequences that encode for
either the first Ig domain or the first Ig domain plus the
acidic box were also identified, but the properties of these
isoforms are not known and no tissue-specific expression
has yet been reported [1].
Activation and signaling of FGFR
FGFR signaling is primarily triggered by the binding of the
receptors to FGF ligands (Table 1), and the subsequent
formation of various complexes to initiate downstream
signal transduction including activation of PLCc, MAPK,
AKT, and STAT cascade (Fig. 3) [19].
The phosphotyrosine residues in the carboxy-terminal
regions of FGFR confer selective and strong binding to Src
homolog 2 (SH2) domain-containing molecules, such as
phospholipase Cc (PLCc) [20, 21]. This interaction results
in the hydrolysis of phosphatidylinositol 4,5-biphosphate
(PIP2) to generate two effectors, inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG) [22]. Accumulation of IP3
further stimulates calcium release from internal stores,
whereas DAG mediates the activation of protein kinase C
(PKC) and other downstream targets such as the Ras/MEK/
MAPK pathway (Fig. 3) [22].
One of the many adaptor proteins which facilitates
signal transduction from FGFRs is the v-crk sarcoma virus
CT10 oncogene homolog (avian) (Crk). Upon exposure to
growth factors, the juxtamembrane tyrosine residue 463 of
FGFR1 is phosphorylated, followed by the transient
phosphorylation of Crk to mediate the co-complexing of
FGFR1 and Crk [23]. Crk has been reported to associate
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Fig. 3 FGFR signaling pathway. FGFs induce FGFR-mediated
signaling pathway by interacting with specific FGFRs and HSPGs.
The macromolecular interactions mediate FGFRs dimerization or
oligomerization and activate multiple signal transduction pathways,
including those involving FRS2, RAS, p38 MAPKs, ERKs, JNKs,
Src, PLCc, Crk, PKC and PI3K. These pathways are negatively
regulated in part by the activities of DUSPs, SPRY, SEF and CBL
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Figure 5. FGFR signaling pathway. FGFs induce FGFR-mediated signaling 
pathway by interacting with specific FGFRs and HSPGs. The macromolecular 
interactions mediate FGFRs dimerization or oligomerization and activate multiple 
signal transduction pathways, including those involving FRS2, RAS, p38 MAPKs, 
ERKs, JNKs, Src, PLCγ, Crk, PKC and PI3K. These pathways are negatively 
regulated in part by the activities of DUSPs, SPRY, SEF and CBL.  
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Figure 6. Presence of internalized beads in autophagosomes after FGF7 
stimulation. (A) HaCaT cells transiently transfected with pEGFP-C2-LC3 construct 
were serum starved or stimulated with FGF7 for 24 h and with inert latex red 
fluorescent beads 0.5 µm in diameter for the last 4 h. Cell nuclei were stained with 
DAPI. Quantitative fluorescence analysis shows that an increase of either the 
number of EGFP-LC3 positive dots per cell and fluorescent bead uptake, as well as 
a partial colocalization between LC3 and fluorescent beads are detectable only 
upon FGF7 stimulation. The quantitative analysis was performed as described in 
Materials and Methods and results are expressed as mean values ± standard errors 
(SE).  Student t test was performed and significance levels have been defined as p 
< 0.05: *p < 0.001 vs the corresponding FGF7-unstimulated cells, **p < 0.001 vs the 
corresponding serum-cultured cells, ***p < 0.01 vs the corresponding FGF7-
unstimulated cells, NS vs the corresponding serum-cultured cells. Bar: 10 µm. (B) 
Ultrastructural analysis of HaCaT cells stimulated with FGF7 in presence of beads 
as described above.  Single (asterisks, i, ii, iii) and clustered beads (asterisks, iv) 
were visible in either single-membrane (arrows, ii) or double-membrane vacuoles 
(arrowheads, ii, iii, iv) corresponding to phagosomes and autophagosomes 
respectively. AV, autophagic vacuole; ER, endoplasmic reticulum; Ly, lysosome; 
M, mitochondrion; Nu, nucleus; PH, phagosome; PM, plasma membrane. Bar: 0.25 
µm.  
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Figure 7. PLCγ signaling is required for FGF7-induced autophagy. (A) HaCaT cells 
were transiently transfected with the FGFR2b WT or with the Y769F FGFR2b 
mutant. The transfection with the kinase negative Y656F/Y657F FGFR2b or with 
pCI-neo empty vector was performed as control. Upon transfection, cells were 
serum-starved and stimulated with FGF7 in the presence of bafilomycin A1 for the 
last 3 h. Western blot analysis shows that FGFR2b Y769F expression, as well as 
FGFR2b kin- expression, inhibits the increase of LC3-II levels induced by FGF7 in 
pCI-neo cells and even more in FGFR2b WT cells. The equal loading was assessed 
using anti-ACTB antibody. For the densitometric analysis, the values from 3 
independent experiments were normalized, expressed as fold increase and 
reported in graph as mean values ± standard deviation (SD). Student t test was 
performed and significance levels have been defined as p < 0.05: *p < 0.05 vs the 
corresponding serum-cultured cells, **p < 0.05 vs the corresponding FGF7-
unstimulated cells, NS vs the corresponding FGF7-unstimulated cells.  (B) HaCaT 
cells were transiently cotransfected with pEGFP-C2-LC3 construct and with the 
FGFR2b WT, with the Y769F FGFR2b mutant, with the kinase negative 
Y656F/Y657F FGFR2b or with pCI-neo empty vector and stimulated with FGF7 as 
above. Immunofluorescence was performed using anti-FGFR2b polyclonal 
antibodies to visualize transfected FGFR2b WT or mutants. Upon FGF7 treatment 
the number of LC3-positive dots per cell is reduced in HaCaT EGFP-LC3/FGFR2b 
Y769F cells, as well as in HaCaT EGFP-LC3/FGFR2b kin- cells, compared to the 
surrounding cells not showing detectable receptor mutant overexpression 
(arrowheads), or to HaCaT EGFP-LC3/pCI-neo and HaCaT EGFP-LC3/FGFR2b 
WT cells.  Differently from the kinase negative dead mutant, both FGFR2b WT 
and FGFR2b Y769F signals appear internalized upon FGF7 stimulation. The 
quantitative analysis and Student t test were performed as above: *p < 0.05 vs 
HaCaT pCI-neo, **p < 0.001 vs HaCaT FGFR2b WT cells. Bar: 10 µm. 
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Figure 8.  The inhibition of PLCγ signaling is accompanied by JNK pathway shut-
down and PKCδ inactivation. (A, B) HaCaT pCI-neo, HaCaT FGFR2b WT and 
HaCaT FGFR2b Y769F cells were serum starved or stimulated with FGF7 as above. 
Western blot analysis shows that the phosphorylation of both JNK1 (A) and 
PKCδ (B) in response to FGF7 stimulation appears attenuated only in HaCaT 
FGFR2b Y769F cells, while AKT and ERK1/2 substrates (A) are highly 
phosphorylated in all cells. The equal loading was assessed using anti-AKT, anti-
ERK1/2, anti-JNK1/2 and anti-PKCδ antibodies. The densitometric analysis and 
Student t test were performed as reported above: (A) *p < 0.05 vs the 
corresponding FGF7-unstimulated cells; **p < 0.01 vs the corresponding FGF7-
unstimulated cells. (B) *p < 0.05 vs the corresponding FGF7-unstimulated cells; NS 
vs the corresponding FGF7-unstimulated cells.  
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Figure 9. HaCaT pCI-neo and HaCaT FGFR2b WT cells were serum starved or 
stimulated with FGF7 in presence or not of the indicated substrate inhibitors as 
reported in Materials and Methods. Western blot analysis performed using 
antibodies directed against the phosphorylated forms of each substrate confirms 
that all the inhibitors were highly specific.  
The equal loading was assessed with anti-AKT, anti-ERK1/2, anti-JNK1/2 and 
anti-PKCδ antibodies. The densitometric analysis was performed as reported 
above  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10
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Figure 10. The inhibition of either JNK1 or PKCδ substrates blocks FGFR2b-
induced autophagy. (A, B, C, D) HaCaT pCI-neo and HaCaT FGFR2b WT were 
serum starved or stimulated with FGF7 in presence or not of the indicated 
substrate inhibitors as reported in Materials and Methods. Western blot analysis 
shows that either AKT inhibitor (A) or MEK1/2 inhibitor (B) do not affect the 
increase of LC3-II levels induced by FGF7, while JNK inhibitor (C) and PKCδ 
inhibitor (D) attenuate it. The equal loading was assessed with anti-ACTB 
antibody. The densitometric analysis and Student t test were performed as 
reported above: (A) *p < 0.05 vs the corresponding FGF7-unstimulated cells; **p < 
0.05 vs the corresponding FGF7-stimulated cells; ***p < 0.01 vs the corresponding 
FGF7-unstimulated cells; NS vs HaCaT pCI-neo cells. (B) *p < 0.05 vs the 
corresponding FGF7-unstimulated cells; **p < 0,01 vs HaCaT pCI-neo cells; ***p < 
0.01 vs the corresponding FGF7-unstimulated cells; NS vs the corresponding 
MEK1/2 inhibitor-untreated cells. (C) *p < 0.05 vs the corresponding FGF7-
unstimulated cells; **p < 0.01 vs the corresponding FGF7-stimulated cells; ***p < 
0.01 vs HaCaT pCI-neo cells; **** p < 0.01 vs the corresponding FGF7-unstimulated 
cells; NS vs the corresponding JNK inhibitor-untreated cells. (D) *p < 0.05 vs the 
corresponding FGF7-unstimulated cells; **p < 0.05 vs the corresponding FGF7-
stimulated cells; ***p < 0.01 vs HaCaT pCI-neo cells; NS vs the corresponding 
PKCδ inhibitor-untreated cells.  
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Figure 11. HKs from light skin and from dark skin were grown in complete 
medium. Western blot analysis performed using anti FGFR2 polyclonal antibodies 
shows that light skin HKs have higher expression of FGFR2b than dark skin 
HKs. The equal loading was assessed with anti-ACTB antibody. The densitometric 
analysis was performed as reported above.  
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Figure 12. FGF7-induced phagocytosis and autophagy are convergent pathways 
only in light skin HKs. HKs from light skin and from dark skin were transiently 
transfected with pEGFP-C2-LC3 construct and serum starved or stimulated with 
FGF7 in the presence of fluorescent beads as reported in figure 6. Quantitative 
fluorescence analysis shows that the increase of the bead uptake and the number 
of LC3-positive dots per cell upon FGF7 stimulation is more evident in light skin 
HKs than in dark ones. A partial colocalization between fluorescent beads and 
LC3 signal (26%) is detected only in light skin HKs. The quantitative analysis and 
Student t test were performed as above: *p < 0.01 vs the corresponding FGF7-
unstimulated cells; **p < 0.05 vs the corresponding FGF7-unstimulated cells; NS vs 
the corresponding serum-cultured cells; •p < 0.01 vs the corresponding serum-
cultured cells; ••p < 0.01 vs the corresponding FGF7-unstimulated cells; •••p < 
0.05 vs the corresponding FGF7-unstimulated cells; ^ p < 0.05 vs the 
corresponding FGF7-unstimulated cells; NS vs the corrisponding FGF7-
unstimulated cells. Bar: 10 µm.   
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Figure 13. 16E5 inhibits FGF7-induced autophagy. (A) HaCaT cells were 
transiently transfected with pCI-neo E5-HA expression vector (HaCaT E5) or with 
the empty vector alone (HaCaT pCI-neo). The 16E5 mRNA transcripts, quantitated 
by real-time relative RT-PCR and normalized with respect to those detected in the 
HPV16-positive cervical epithelial cell line W12 at the passage 6 (W12p6), are 
highly expressed only in HaCaT E5 cells. (B, C) HaCaT E5 and HaCaT pCI-neo 
cells were serum-starved in the presence or absence of FGF7 100 ng/ml for 24 h. 
Western blot analysis shows that, upon FGF7 stimulation, the LC3-II band is 
reduced (B), while the SQSTM1 band is enhanced (C), in HaCaT E5 cells compared 
to HaCaT pCI-neo cells. The equal loading was assessed using anti-β actin 
antibody. The densitometric analysis and Student t test were performed as 
reported above: (B, C) *p < 0.05 vs the corrisponding unstimulated cells, **p < 0.05 
vs the corresponding HaCaT pCI-neo cells. (D) HaCaT cells were transiently 
cotransfected with pEGFP-C2-LC3 construct and pCI-neo E5-HA (HaCaT EGFP-
LC3/E5) or pCI-neo empty vector (HaCaT EGFP-LC3) before stimulation with 
FGF7 as above. Immunofluorescence was performed using anti-HA monoclonal 
antibody (red), to visualize 16E5, and cell nuclei were stained with DAPI. Upon 
FGF7 treatment, the number of LC3-positive dots per cell is increased in HaCaT 
EGFP-LC3 cells and in HaCaT EGFP-LC3/E5 cells not showing 16E5 staining 
(arrows), but is reduced in HaCaT EGFP-LC3/E5 cells strongly labeled for 16E5 
(arrowhead) if compared to serum-starved HaCaT EGFP-LC3 cells The 
quantitative analysis and Student t test were performed as above: *p < 0.001 vs the 
corresponding serum starved-cells, **p < 0.001 vs the corresponding HaCaT EGFP-
LC3 cells. Bar: 10 µm.  
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Figure 14. The inhibitory effect of 16E5 on FGF7-triggered autophagy depends on 
FGFR2b expression and signaling. (A) HaCaT cells were transfected with 16E5 
cDNA (HaCaT E5), with a small interfering RNA for FGFR2/Bek (HaCaT FGFR2b 
siRNA) or with an unrelated siRNA (HaCaT control siRNA) as control. 
Alternatively cells were cotransfected with FGFR2b WT cDNA and with FGFR2b 
siRNA. Cells were then stimulated with FGF7 as above. Western blot analysis 
shows that, upon FGF7 stimulation, both FGFR2b and LC3-II bands are reduced, 
while the SQSTM1 band is increased either in 16E5-transfected and FGFR2b-
depleted cells. (B) Cells were transiently transfected with 16E5 (HaCaT E5) or 
cotransfected with 16E5 and pCI-neo vector containing human FGFR2b WT 
(HaCaT E5/FGFR2b WT) or the kinase negative mutant FGFR2b Y656F/Y657F 
(HaCaT E5/FGFR2b kin-) and stimulated with FGF7 as above. Western blot 
analysis shows that the decrease of LC3-II as well as the increase of SQSTM1 
induced by 16E5 expression is counteracted only by FGFR2b WT overexpression. 
The densitometric analysis and Student t test were performed as reported above: 
(A) ^, ^^^, ***p < 0.05 and *p < 0.01 vs the corrisponding HaCaT control siRNA 
cells, ^^p < 0.05 and **p < 0.01 vs the corrisponding HaCaT FGFR2b siRNA cells; 
(B) *, ^p < 0.05 vs HaCaT E5 cells.  
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Figure 15. 16E5 inhibits also the serum starvation-induced autophagy. (A, B) 
HaCaT pCI-neo and HaCaT E5 cells were kept in complete medium or serum-
starved for 24 h or 48 h. Western blot analysis shows that in HaCaT E5 cells the 
serum deprivation-induced progressive increase of LC3-II band is reduced, while 
the decrease of SQSTM1 is blocked. The densitometric analysis and Student t test 
were performed as above: (A) *p < 0.01 vs the corresponding HaCaT pCI-neo cells, 
**p < 0.05 vs the corresponding HaCaT pCI-neo cells; (B) *, **p < 0.05 vs the 
corresponding HaCaT pCI-neo cells. (C) Immunofluorescence analysis performed 
in HaCaT EGFP-LC3 and HaCaT EGFP-LC3/E5 cells serum-starved as above 
shows no increase in LC3-positive dots in cells expressing 16E5 (arrowheads) 
compared to HaCaT EGFP-LC3 (arrow). The quantitative analysis and Student t 
test were performed as above: *p < 0.005 vs the corresponding serum cultured-
cells, **p < 0.005 vs the corresponding HaCaT EGFP-LC3 cells. Bar: 10 µm.  
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Figure 16. 16E5 inhibits autophagosome assembly. (A) HaCaT mCherry-EGFP-
LC3 and HaCaT mCherry-EGFP-LC3/E5 cells were serum-starved or treated with 
FGF7 as above. Immunofluorescence analysis shows that in E5 expressing cells the 
number of yellow dots corresponding to newly assembled autophagosomes is 
decreased, while the red dots corresponding to autolysosomes are not increased 
compared to control cells. The quantitative analysis and Student t test were 
performed as above: *p < 0.05, **p < 0.01 vs the corresponding HaCaT mCherry-
EGFP-LC3 cells. Bar: 10 µm (B) HaCaT pCIneo and HaCaT pCI-neo/E5 cells were 
serum-starved or treated with FGF7 in the presence or absence of leupeptin (LEU) 
as reported in Materials and Methods. Western blot shows that in 16E5 expressing 
cells the LC3-II levels are significantly reduced also in the presence of the inhibitor 
of the lysosomal degradation. The densitometric analysis and Student t test were 
performed as reported above: * and **p < 0.05 vs the corresponding HaCaT pCI-
neo cells, *** and ****p < 0.01 vs the corresponding HaCaT pCI-neo cells.  
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Figure 17. Impairment of autophagy in cells stably expressing 16E5. (A) HaCaT 
pMSG and HaCaT pMSG E5 cells were left untreated (0 h) or treated with Dex for 
12 h or 24 h. The 16E5 the increasing mRNA transcript levels were quantitated by 
real-time relative RT-PCR and normalized with respect to those detected in W12p6 
cells. (B) Cells were kept in complete medium or either serum-starved or 
stimulated with FGF7 for 24 h in presence or absence of Dex induction. Western 
blot analysis shows that in serum-kept cells (left panel) the very weak band 
corresponding to LC3-II is decreased at 12 h and 24 h of Dex treatment in HaCaT 
pMSG E5 cells, while no changes in the band intensity are observed in HaCaT 
pMSG cells. Upon serum starvation (middle panel) or FGF7 stimulation (right 
panel) the evident increase of LC3-II band is abolished by Dex treatment only in 
HaCaT pMSG E5 cells, but not in control cells. In absence of Dex treatment, the 
increase of LC3-II protein induced FGF7 is lower in HaCaT pMSG E5 than in 
control cells. The densitometric analysis and Student t test were performed as 
above: *, **p < 0.05 vs the corresponding Dex-untreated cells, • p < 0.05 vs the 
corresponding serum-cultured cells, •• NS vs the corresponding Dex-untreated 
cells, ••• NS vs the corresponding HaCaT pMSG cells, ••••, ••••• p < 0.05 vs 
the corresponding Dex-untreated cells, ^, ^^p < 0.05 vs the corresponding FGF7- 
unstimulated cells, ♦♦♦NS vs the corresponding Dex-untreated cells, ^^^p < 0.01 
vs the corresponding FGF7-unstimulated cells, ^^^^p < 0.05 vs the corresponding 
Dex-untreated cells, ^^^^^p < 0.01 vs the corresponding Dex-untreated cells, ♦♦♦p 
< 0.05 vs the corresponding HaCaT pMSG cells. (C) Ultrastructural analysis of 
HaCaT pMSG and HaCaT pMSG E5 cells stimulated with FGF7 for 24 h in 
presence of Dex: the number of double-membrane autophagic vacuoles (asterisks) 
is lower in HaCaT pMSG E5 (right panel) compared to HaCaT pMSG cells (left 
and middle panels). ER, endoplasmic reticulum; M, mitochondrion; NM, nuclear 
membrane; PM, plasma membrane; G, Golgi complex. Bars: 0.5 µm.  
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Figure 18. The unresponsiveness of W12p6 cells to autophagic stimuli depends on 
16E5 expresssion. (A) Cells were kept in complete medium or serum-starved in 
the presence or absence of FGF7 for 24 h. Western blot shows no changes in the 
levels of LC3-II marker in W12p6 cells upon both serum deprivation or FGF7 
stimulation. (B) W12p6 cells were transfected with EGFP-LC3 and treated as 
above. Fluorescence analysis shows an increase in the number of LC3-positive 
dots per cell after serum starvation and/or FGF7 stimulation in HaCaT EGFP-LC3 
and HKs EGFP-LC3 control cells, but not in W12p6 EGFP-LC3 cells. The 
quantitative analysis and Student t test were performed as above: *p < 0.05 vs the 
corresponding EGFP-LC3 HaCaT cells; **, ***p > 0.001 vs the corresponding EGFP-
LC3 HaCaT cells or vs the corresponding EGFP-LC3 HKs. (c) W12p6 cells were 
transfected with E5 siRNA or with an unrelated siRNA as control and treated as 
above. The LC3-II levels are progressively increased by serum deprivation and by 
FGF7 in W12p6 E5 siRNA, while no changes are observed in W12p6 control 
siRNA. The densitometric analysis and Student t test were performed as above: 
NS vs the corresponding serum-cultured cells; *, **p < 0.05 vs the corresponding 
W12p6 control siRNA cells. (D) W12p6 cells were cotransfected with EGFP-LC3 
and with E5 siRNA or with a control siRNA and treated as above. Fluorescence 
approaches show a significant increase of LC3-positive dots in 16E5-depleted W12 
cells upon serum deprivation and even more upon FGF7 stimulation. No increase 
is found in control siRNA-transfected cells. *, **p < 0.001 vs the corresponding 
control siRNA. Bars 10 µm. 
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Figure 19. E5 siRNA induce an efficient depletion of 16E5 protein in transiently 
transfected HaCaT E5 cells. HaCaT cells were doubly transfected with pCI-neo E5-
HA cDNA and E5 siRNA or control unrelated siRNA. Western blot analysis using 
anti-HA monoclonal antibody shows that the band at the molecular weight 
corresponding to 16E5 protein is decreased in HaCaT E5 cDNA/E5siRNA as 
expected. 
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Figure 20. 16E5 expression down-modulates the autophagy gene expression in 
HaCaT cells. (A, B) HaCaT pCI-neo and HaCaT E5 cells were kept in complete 
medium or serum-starved or stimulated with FGF7 as above. Real-time relative 
RT-PCR of key regulatory autophagy genes (A) or p53-target autophagic (ULK1, 
ULK2, ATG4a, ATG7) or autophagy-independent (p21, 14–3-3-σ) genes (B). 
Results are expressed as mean ± standard error (SE) from three different 
experiments in triplicate. Student t test was performed and significance levels 
have been defined as p < 0.05: (A) *p < 0.05 and **p < 0.01 vs the corresponding 
HaCaT pCI-neo cells, NS vs the corresponding HaCaT pCI-neo cells, ^p < 0.05 vs 
the corresponding FGF7-unstimulated cells. (B) *, **, ^, ^^p < 0.05 vs the 
corresponding HaCaT pCI-neo cells, NS vs the corresponding FGF7-unstimulated 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21
A
FBS
FGF7
- - - 
+- + 
- 
- 
- - + 
+- + 
- 
- 
1
6
E
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum  +      -     -       -      -
KGF     -    -     -       +     +
0
1
2
3
4
5
Serum     -     -       -     -
NS
**
KGF        -     -          +
B
E
C
N
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Serum     -      -       -     -
KGF        -      -      +    +
A
T
G
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
****
*** *****
NS vs the corresponding HKs pCI-neo cells,  
* p< 0.05 vs the corresponding KGF-unstimulated cells, 
** p< 0.05 vs the corresponding HKs pCI-neo cells
***, ***** p< 0.001 vs the corresponding HKs pCI-neo cells,  
**** p< 0.005 vs the corresponding KGF-unstimulated cells, 
1
6
E
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Seru  + - - - -
K F -  - - + +
0
1
2
3
4
5
Seru  - - -  -
NS
**
K F   - + 
B
E
C
N
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Seru  - - - -
K F - - + +
A
T
G
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
****
*** *****
S vs the cor esponding Ks p I-neo cel s, 
* p< 0.05 vs the cor esponding K F-unsti ulated cel s, 
** p< 0.05 vs the cor esponding Ks p I-neo cel s
***, ***** p< 0.001 vs the cor esponding Ks p I-neo cel s, 
**** p< 0.005 vs the cor esponding K F-unsti ulated cel s, 
-
-
- - - 
+-  
- 
- 
1
6
E
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
 
 
B
E
C
N
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
A
T
G
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
- - - 
+- + 
- 
- 
L
C
3
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum         -            -
KGF        -      -         +
^
0
0.2
0.4
0.6
0.8
1
1.2
1.4 ^^
^^^    
HKs pCI-neo
HKs E5
W12p6
^ p< 0.005 vs the corresponding HKs pCI-neo cells,
^^^ p< 0.001 vs the corresponding HKs pCI-neo cells, 
^^ p< 0.0051 vs the corresponding KGF-unstimulated cells,
NS vs the corresponding HKs pCI-neo cells,  
* p< 0.01 vs the corresponding HKs pCI-neo cells, 
**, *** p< 0.05 vs the corresponding HKs pCI-neo cells, 
 
U
L
K
2
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
NS
*
Serum     -      -       -     -
**
KGF        -      -      +    +
A
T
G
4
a
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
***
L
C
3
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
^
0
0.2
0.4
0.6
0.8
1
1.2
1.4 ^^
^^^    
HKs pCI-neo
HKs E5
W12p6
^ p< 0.005 vs the corresponding HKs pCI-neo cells,
^^^ p< 0.001 vs the corresponding HKs pCI-neo cells, 
^^ p< 0.0051 vs the corresponding KGF-unstimulated cells,
NS vs the corresponding HKs pCI-neo cells,  
* p< 0.01 vs the corresponding HKs pCI-neo cells, 
**, *** p< 0.05 vs the corresponding HKs pCI-neo cells, 
 
U
L
K
2
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
NS
*
Serum     -      -       -     -
**
KGF        -      -      +    +
A
T
G
4
a
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
***
Serum     -      -       -     -
KGF        -      -      +    +
A
T
G
7
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
^ p< 0.001 vs the corresponding HKs pCI-neo cells, 
^^ p< 0.05 vs the corresponding HKs pCI-neo cells, 
NS vs the corresponding KGF-unstimulated cells,  
*,** p< 0.05 vs the corresponding HKs pCI-neo cells
 
^
^^    
HKs pCI-neo
HKs E5
W12p6
p
2
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
HKs pCI-neo
HKs E5
W12p6
**
*
L
C
3
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Seru  -  -  -  -
K F  -  -  +  +
^
0
0.2
0.4
0.6
0.8
1
1.2
1.4 ^^
^^^  
Ks p I-neo
Ks E5
12p6
^ p< 0.005 vs the corresponding s p I-neo ce ls,
^^^ p< 0.001 vs the corresponding s p I-neo ce ls, 
^^ p< 0.0051 vs the corresponding F-unsti ulated ce ls,
 vs the corresponding s p I-neo ce ls,  
* p< 0.01 vs the corresponding s p I-neo ce ls, 
**, *** p< 0.05 vs the corresponding s p I-neo ce ls, 
 
U
L
K
2
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Seru  -  -  -  -
K F  -  -  +  +
0
0.2
0.4
0.6
0.8
1
1.2
S
*
Seru  -  -  -  -
**
K F  -  -  +  +
A
T
G
4
a
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
***
B
Serum     -      -       -     -
KGF        -      -      +    +
A
T
G
7
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
^ p< 0.001 vs the corr sponding HKs pCI-neo cells, 
^^ p< 0.05 vs the corr sponding HKs pCI-neo cells, 
NS vs the corr sponding KGF-unstimulated cells,  
*,** p< 0.05 vs the corr sponding HKs pCI-neo cells
 
^
^^    
HKs pCI-neo
HKs E5
W12p6
p
2
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
HKs pCI-neo
HKs E5
W12p6
**
*
FB
FGF7
 
 
- 
- 
-
+
-
-
- - -
-  
- 
- 
- - - 
+- +
- 
- 
Figure 21
FBS
FGF7
- - - 
+- + 
- 
- 
- - - 
+- + 
- 
- 
- - - 
+- + 
- 
- 
- - - 
+- + 
- 
- 
*, **, *** p< 0.05 vs the corresponding siRNA Cx cells,
U
L
K
2
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -     -       -    -
KGF              -      +    +
*
0
0.5
1
1.5
2
2.5
A
T
G
4
a
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.5
1
1.5
2
2.5
**
***
D
A
T
G
7
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
^ ^^
0
0.2
0.4
0.6
0.8
1
1.2
p
2
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
HKs
W12p6 E5 siRNA
W12p6 control siRNA
****
**** p< 0.05 and ***** p<0,005  vs the corresponding siRNA Cx cells
^ p<0.005 and ^^ p<0,05 vs , vs the corresponding siRNA Cx cells
*****
- 
+ 
- 
- 
- 
+ 
- 
- 
- 
+ 
- 
- 
- 
+ 
-
-
*, *, *  p< 0. 5 vs the corresponding siRNA Cx cells,
U
L
K
2
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -  - -  
KGF        -  - +   
*
0
0.5
1
1.5
2
2.5
A
T
G
4
a
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.5
1
1.5
2
2.5
**
**
A
T
G
7
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -      -       -     -
KGF        -      -      +    +
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
^ ^^
0
0.2
0.4
0.6
0.8
1
1.2
p
2
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
HKs
W12p6 E5 siRNA
W12p6 control siRNA
****
****  . 5 and ***** p<0,005  vs the corresponding siRNA Cx cells
^ p<0.005 and ^^ p<0,05 vs , vs the corresponding siRNA Cx cells
*****
C
FBS
FGF7
- - - 
+- + 
- 
- 
- - - 
+- + 
- 
- 
- - - 
+- + 
- 
- 
- 
+ 
- 
- 
- 
+ 
- 
- 
- 
+ 
- 
- 
HKs
W12p6 E5 siRNA
W12p6 control siRNA
***
****
L
C
3
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
* p< 0.001 and ** p<0,005 vs the corresponding control siRNA cells;
***, **** p>0,0 vs the corresponding control siRNA cells.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Serum     -      -       -     -
KGF        -      -      +    +
B
E
C
N
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.5
1
1.5
2
2.5
!"#$%
*
**
NS
NS
&
&'(
&')
&'*
&'+
%
%'(
%')
%'*
%'+
(
A
T
G
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
Serum     -  -  -  -
KGF        -  -  +  +
B
E
C
N
1
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
0
0.5
1
1.5
2
2.5
!"#$%
*
**
NS
NS
&
&'(
&')
&'*
&'+
%
%'(
%')
%'*
%'+
(
A
T
G
5
 m
R
N
A
 f
o
ld
 e
x
p
re
s
s
io
n
 
	 74	
Figure 21. 16E5 depletion in the W12p6 cervical carcinogenesis model restores the 
autophagic gene expression. (A,B) HKs pCI-neo and HKs E5 cells were kept in 
complete medium or serum-starved or stimulated with FGF7 as above. Real-time 
relative RT-PCR of key regulatory autophagy genes (A) or p53-target genes (B). (C, 
D) W12p6 control siRNA and W12p6 E5 siRNA cells and HKs were treated as 
above. Real-time relative RT-PCR of key regulatory autophagy genes (C) or p53-
target genes (D). Results are expressed as mean ± standard error (SE). Student t 
test was performed and significance levels have been defined as above: (A) *p < 
0.05 and **** and ^^p < 0.005 vs the corresponding FGF7-unstimulated cells, **p < 
0.05, ^p < 0.005 and ***, *****, ^^^p < 0.001 vs the corresponding HKs pCI-neo 
cells, NS vs the corresponding HKs pCI-neo cells; (B) *, **, ***, ^^p < 0.05 and ^p < 
0.001 vs the corresponding HKs pCI-neo cells, NS vs the corresponding HKs pCI-
neo cells; (C) *, **p < 0.001 and ***, ****p < 0.05 vs the corresponding W12p6 
control siRNA, NS vs the corresponding W12p6 control siRNA; (D) *, **, ***, ^^p < 
0.05 and ****, *****, ^p < 0.005 vs the corresponding W12p6 control siRNA. 
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Figure 22. Schematic drawing of the proposed role of FGFR2b and its PLCγ 
signaling in the regulation of autophagy and phagocytosis interplay. FGF7-
mediated FGFR2b activation induces phosphorylation of the Y769 residue, which 
is required for activation and recruitment of PLCγ to the receptor. PLCγ signaling 
in turn induces both phagocytosis through diacylglycerol (DAG) formation and 
autophagy through JNK1 activation via PKCδ. The two membrane pathways 
partially converge toward lysosomal degradation.  
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